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 ABSTRACT  
The quality of the T cells that are selected for expansion and adoptive transfer 
has been identified as a critical factor that determines the persistence, and 
therefore, efficacy, of transferred cells. The memory T-cell compartment is 
heterogeneous and encompasses multiple T cell subsets with divergent 
properties. Latent human cytomegalovirus (CMV) infection is controlled by a 
limited repertoire of immunodominant T cells specific for viral peptides. The 
antigen-specific T cell subsets responsible for maintaining memory T cells and 
repopulating them in response to periodic viral reactivations are not well 
characterized. In the first chapter of my thesis work, I developed a human 
xenograft model in NOG mice to conduct comparisons of CMV-specific TCM and 
TEM derived cells in vivo, when administered together with the cytokine IL-2 or IL-
15. These studies specifically compared CMVpp65 specific TCM and TEM derived 
cells as to their capacity to selectively target, accumulate in and induce inhibition 
of human colon carcinoma xenograft transduced to express CMVpp65. The 
experiments also evaluated the kinetics and level of T-cell accumulation in these 
	
	
targets and their persistence both in the xenografts and other tissues, particularly 
the marrow. In the second chapter of my thesis work, I focused on identifying the 
most effective T-cell memory population that would provide higher in vivo 
proliferation, survival, and overall functional activity. The studies comparatively 
evaluated CMVpp65 epitope-specific tetramer+ T-cell populations within the 
memory T-cell compartment as to their origins, phenotype, functional attributes, 
T-cell clonal diversity, proliferation and survival. In the third chapter of my thesis 
work, I evaluated the differential functional activity of low and high affinity 
chimeric antigen receptor constructs encoding T-cell receptor mimics specific for 
an immunogenic peptide of an oncognic protein, WT-1, presented by HLA 
A0201.  
Overall, the thesis work has implications for the design of T cell-based 
immunotherapies. First, the studies indicate that while TCM and TEM derived T-
cells exhibit differences in phenotype and in the kinetics and degree of their 
respective accumulations in CMVpp65+ CoCa xenografts, their antigen-specific 
activities and their persistence in vivo were fairly equivalent. The differences lies 
in the cytokine treatment: in IL-15/IL-15Rα treated mice there was a more 
prolonged persistence of both TCM and TEM derived T-cells compared to IL-2 
treated mice. Second, the studies suggested Tet+ TSCM rather than Tet+ TN are 
the principal reservoir for rapid repopulation of immunodominant TEM cells in the 
circulation. TSCM could potentially provide better disease control by facilitating 
early recovery of more short-lived immunodominant virus-specific TEM cells that 
	
	
normally control latent infection and thereby provide sustained long-term 
protection from disease. Finally, the studies validate the superior specific binding 
and HLA-restricted WT-1 peptide specific cytoxicity of T-cell expressing the high 
affinity CAR against HLA A0201+WT-1+ human tumor cells compared to low 
affinity CAR against the same antigen.  
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THESIS INTRODUCTION  
Adoptive T-cell therapy using naturally occurring antigen-specific T cells or 
antigen targeted genetically engineered T-cells has demonstrated clinical efficacy 
in the treatment of infections and cancer. Infusions of ex vivo expanded, naturally 
occurring tumor infiltrating lymphocytes (TILs) responding to self-tumor antigens, 
have successfully mediated durable, complete tumor regressions in a proportion 
of patients with melanoma (1).  Such TILs potentially target somatic mutations 
exclusive to each cancer, which are responsible for their clinical activity.  More 
recently, the ability to genetically engineer lymphocytes to express conventional 
T cell receptors or chimeric antigen receptors has further extended the spectrum 
for successful application of adoptive cell therapy for cancer treatment (2).   
Adoptive immunotherapy is an approach that focuses on the therapeutic transfer 
of antigen-specific T cells targeted to a specific viral or tumor antigen. The 
maximal efficacy of this approach can be realized when the infused T-cells can 
effectively engraft in the recipient host, or, at least, continue to replicate and 
regenerate functional effector and memory T cell populations for extended 
periods of time after initial cell transfer, and thereby provide ongoing immunity 
against disease. This can be achieved if autologous virus-specific or tumor-
reactive T-cells can be generated in vitro, and when such T-cells are selectively 
expanded from a marrow transplant donor and infused into the patient after 
transplant (3).  However, a deeper understanding of the types and growth 
requirements of the T-cells that are effective is still needed if adoptive therapies 
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are to be consistently able to induce lasting responses. Similarly, since 
autologous T-cells cannot be consistently generated and are often inactive, 
alternative approaches such as the use of banked third party T-cells of 
demonstrated activity will be required for broad application of this approach.  
In 1986, Rosenberg et al. showed that lymphocytes infiltrating the tumor stroma 
were a concentrated source of lymphocytes capable of recognizing tumor in vitro.  
These observations were validated in murine tumor models, in which the 
adoptive transfer of these tumor-infiltrating lymphocytes, expanded in IL-2 prior to 
infusion, could mediate regression of established tumors (4). In 1988, Rosenberg 
et al. first reported objective regression of cancer upon infusion of ex-vivo 
expanded autologous TILs in patients with metastatic melanoma (1). To further 
improve their efficacy, this approach was modified to include a lymphodepleting 
chemotherapy regimen prior to TIL transfer.  It was postulated that the 
lymphodepletion would decrease the burden of regulatory T-cells as well as other 
myeloid suppressor cells, thereby rendering a more supportive immune 
environment for the activity of transferred cytotoxic lymphocytes (5).  
Since then, the application of this treatment approach has further evolved to 
include the use of genetically modified T-cells transduced to express TCRs or 
chimeric antigen receptors targeted to tumor antigens.  Morgan et al. first 
demonstrated that the administration of normal circulating lymphocytes 
transduced with a retrovirus encoding a TCR that recognized the MART-1 
melanoma antigen could mediate tumor regressions (6). Lymphocytes 
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transduced to express a chimeric antigen receptor (CAR) against CD19 were 
shown in 2010 to mediate regression of an advanced B cell lymphoma (7). In 
sum, naturally occurring or genetically engineered T cells set the stage for the 
extended development of adoptive cell therapy.   
In recipients of allogeneic hematopoietic stem cell transplant (HSCT), T cell 
responses against pathogens can also be reconstituted by adoptive transfer of 
pathogen specific T cells derived from the quiescent memory T-cell pool of the 
donor.  In 1991, Riddell et al, first demonstrated that adoptive transfer of cloned 
transplant donor derived T cells sensitized in vitro could prevent CMV infections 
in HSCT recipients without causing GVHD (8). In 1994, Papadopoulos et al. (9) 
at MSKCC demonstrated that adoptive transfer of unselected lymphocytes 
containing as few as 600 EBV-specific CTL population from an HCT donor could 
induce durable complete remission of EBV lymphomas complicating allogeneic 
T-cell depleted transplants. Subsequent studies confirmed that adoptively 
transferred virus-specific T cell clones or polyclonal T cells specific for CMV or 
EBV, that were isolated and expanded from seropositive stem cell donors, could 
effectively clear CMV infections and EBV lymphomas in HSCT recipients (10, 
11).  
In studies using both tumor antigen selective and virus specific T-cell transfers, 
the infused T-cells have varied significantly in their persistence after transfer. 
Limitations to the persistence of the T-cells have been potentially ascribed to T-
cell senescence or exhaustion. These limitations have major clinical significance 
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since the persistence of transferred antigen-specific T cells in the blood, 
measured by clonotypic analysis of T cell receptor gene sequences or by MHC 
tetramer staining, has been correlated with antitumor activity (12). Tumor-
reactive T cells infiltrating the tumor microenviroment in cancer patients acquire a 
terminally differentiated effector phenotype, which may limit their ability to 
proliferate and survive after adoptive transfer. However, Dudley and colleagues 
(5) showed that administering lymphodepleting chemotherapy prior to T-cell 
infusion can enhance the initial expansion of the transferred T-cell in vivo, and 
thereby potentially contribute to an enhanced persistence of infused T-cells. That 
lyophodepletion prior to adoptive transfer radically increases the initial 
proliferation and population size of the transferred T-cells has been repeatedly 
confirmed, and variously ascribed to homeostatic expansion within lympho-
depleted mice, responses to increased levels of cytokines such as IL-15 and IL-7 
generated in response to lyphodepletion and/or elimination of regulatory T-cell 
populations. However, the in vivo persistence of infused T cells still remains 
unpredictable in individual patients. An alternative approach that has been 
proposed to enhance the persistence of transferred T-cells is to isolate T cells 
that preserve a less differentiated phenotype based on the hypothesis that such 
T-cells would provide superior proliferation, survival, and sustained effector 
function in vivo. Studies in a non-human primate model in which autologous gene 
marked-CMV-specific T cell clones derived from sorted central or effector 
memory T-cell subsets (TCM or TEM) were adoptively transferred, demonstrated 
that TCM derived clones could persist for months after adoptive transfer and could 
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also re-establish diverse memory subsets.  These data illustrated that, even after 
in vitro activation and culture, therapeutic T cells derived from TCM have a 
superior capacity to persist in vivo (13).  
Under physiological conditions, antigen-specific T cells originate from a small 
number of naïve precursor cells that expand vigorously upon initial priming, and 
acquire effector functions. Following this effector phase, most T-cells undergo 
senescence, with only a small fraction that survive beyond the contraction phase 
and persist as memory T cells that then serve to provide the secondary 
response. Long-lived memory T cells are subdivided phenotypically as well as 
functionally into different subsets. This phenotypic and functional diversity within 
epitope-specific T cell populations generated during infection, is increasingly 
recognized to be critical for the quality of antigen-specific immunity. Memory T 
cells can be phenotypically sub classified based on distinct expression patterns 
of the lymph node–homing molecules CD62L and CCR7, into central memory T 
cells (TCM) and effector memory T cells (TEM).  The expression patterns of these 
molecules translate into migratory differences; wherein, TCM cells continuously re-
circulate via the blood stream to lymphoid organs whereas TEM cells preferentially 
migrate to targeted tissues and not to lymphoid tissues (14). The recent 
identification of tissue resident memory T cells (TRM), which might be further 
subdivided depending on the respective organ they reside in, further adds to the 
complexity and diversity of the memory T cell compartment (15). More recently, 
the expression of CD95, also known as FAS, in naïve phenotype T cells now 
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defines a new memory T cell subset in humans and mice, designated stem cell 
memory T cells (TSCM).  TSCM cells have a high proliferative capacity and are both 
self-renewing and multipotent, in that they can further differentiate into other T 
cell subsets, including TCM and TEM cells(16). Recent evidence also supports a 
role for CD4+ helper T cells in sustaining the proliferative potential and 
persistence of CD8+ effector memory T cells. For certain antigens, such as 
adenovirus, CD4+ T cells may also respond directly as effector cells and mediate 
the clearance of virus-infected host cells (17).  
To develop an approach for enhancing persistence and overall efficacy of 
adoptive immunotherapy, the studies conducted during the course of this thesis 
project focused on identifying the most effective T-cell memory population that 
would provide higher in vivo proliferation, survival, and overall functional activity. 
The studies comparatively evaluated antigen-specific T-cell populations within 
the memory T-cell compartment as to their origins, phenotype, functional 
attributes, proliferation and survival, as well as their in vivo homing and 
persistence in humans. Later, through TCR sequencing analysis of sorted T-cell 
populations, a lineage relationship within epitope specific T cells was elucidated.  
A series of studies also evaluated the differential functional activity of low and 
high affinity chimeric antigen receptor constructs encoding T-cell receptor mimics 
specific for an immunogenic peptide of an oncognic protein, WT-1, presented by 
HLA A0201.  
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CHAPTER ONE 
Comparative analysis of the contribution of the cytokines IL-2 and IL-
15/IL15Rα complex to the engraftment, antigen-targeted accumulation, 
effector function and persistence of human central memory and effector 
memory derived CMV specific T-cells in immunodeficient mice 
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1. Introduction 
The adoptive transfer of antigen-specific T cells that have been expanded ex vivo 
is being actively pursued to treat infections and malignancy in humans. Ex vivo 
expanded antigen-specific T cell clones have provided a means for treating 
patients with specific types of cancer such as melanoma by providing a patient 
with an antigen-specific tumoricidal immune response. While the results of early 
clinical trials support the use of adoptively transferred T cells as a strategy for the 
treatment of melanoma, they have also elucidated potential obstacles to these 
therapies (12, 18). In particular, a major limitation to the efficacy of adoptive 
immunotherapy in humans is the failure of cultured T cells, particularly cloned T 
cells, to persist in vivo. The basis for the poor survival of the transferred cells is 
still poorly understood.  
The persistence of transferred tumor-reactive T cells, either generated from the 
blood or expanded directly from tumor infiltrating lymphocytes, has not been 
consistent, even when the host has received lymphodepleting chemotherapy 
before T cell transfer and is also treated with IL-2 (19). In adoptively transferred 
virus-specific T cells, the effector T cells are derived from virus-specific memory 
T cells isolated from immune donors. However, studies in which virus specific T-
cell clones or gene marked polyclonal T-cell lines have been adoptively 
transferred have shown that not all T effector cells derived from memory 
precursors are capable of durable engraftment (13, 20). 
The pool of lymphocytes from which CD8 T cells for adoptive immunotherapy can 
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be derived includes naïve T cells and antigen-experienced memory T cells, which 
can be divided into central memory (TCM) and effector memory (TEM) subsets that 
differ in phenotype, homing, and function. TCM, which express CD62L and CCR7, 
reside predominantly in lymph nodes where they are capable of extensive 
proliferation and differentiation upon antigen re-encounter. On the other hand, 
TEM, which lack the expression of CD62L and CCR7, are prevalent in the blood 
and peripheral tissues, and capable of rapid accumulation in and lysis of virus-
infected or malignant cells expressing the targeted antigen. In a nonhuman 
primate model system, virus-specific effector CTL derived from TCM, but not TEM, 
established persistent, functional T cell immunity following adoptive transfer to 
lymphoreplete healthy macaques (13).  Furthermore, adoptive transfer of human 
antigen-specific CD8 T cells derived from TCM have exhibited superior 
engraftment in human NOG mice supplemented with low dose IL-15 when 
compared with such T-cells derived from TEM (21).   
IL-15 can sustain T cell proliferation without the robust pro-differentiating activity 
that characterizes IL-2. Although IL-2 promotes T cell differentiation into T 
effector cells, priming of T cells in the presence of IL-15 results in the generation 
of T cells with the phenotypic, functional, metabolic and gene expression 
attributes found in naturally arising TCM cells (22, 23). As a result, tumor-reactive 
T cells have exhibited greater antitumor responses when generated in the 
presence of IL-15 than when grown in the presence of IL-2 (22). To better 
understand differences in the engraftment of TCM and TEM derived T cells in the 
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presence of IL-2 or IL-15, we created a humanized mouse model in which human 
CMVpp65 specific T-cells of defined epitope specific and HLA restriction are 
adoptively transferred into immunodeficient NOG mice bearing human tumor 
xenografts that do or do not express CMVpp65, the immunodominent protein of 
human CMV. In order to be able to better examine conditions and attributes of 
CMV-specific T cells that contribute to their activity against infected human cells, 
we employed a human colon carcinoma, which, like human colon epithelial cells 
can be lytically infected by CMV, and transduced this carcinoma to express the 
antigen CMVpp65. We then compared TCM and TEM derived CMVpp65 specific T-
cells for their capacity to achieve sustained engraftment accumulate specifically 
in targeted CMVpp65+ tumors and induce regression of these tumors. Our data 
demonstrate that human CMV-specific T cells derived from TCM and TEM achieve 
similar levels of engraftment, and that mice co-treated with IL-15/IL-15Rα but not 
IL-2 have superior engraftment and provide superior CMVpp65-specific, HLA-
restricted antitumor activity. The engrafted TCM and TEM derived HLAA0201 
restricted CMVpp65-specific T-cells preferentially accumulate in the colon 
carcinoma xenografts coexpressing CMVpp65 and HLAA0201 as well as in the 
bone marrow in the mice treated with IL-15/IL-15α. Furthermore, the T-cells in 
the marrow are functional, exhibiting antigen-specific IFN-r production and T cell 
proliferation when harvested and expanded to CMVpp65 ex vivo.  
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2. Materials and Methods  
Donors 
Blood samples were obtained from healthy volunteer HLA-A0201+ CMV-
seropositive donors. High resolution HLA typing was performed by analysis of 
HLA allele-specific nucleotide sequences using standard high-resolution typing 
techniques. CMV serostatus was determined by standard serologic techniques in 
the clinical microbiology laboratory at Memorial Sloan-Kettering Cancer Center.  
Generation of CMV-specific T cell clones 
PBMC were isolated from whole blood by Ficoll-Hypaque density gradient 
separation (Accurate Chemical & Scientific Corporation, Westbury, NY USA). T 
cells were subsequently enriched from PBMC by depletion of CD19+, CD14+, and 
CD56+ cells, using mAb-coated immunomagnetic beads (Pan T-Cell Isolation Kit II, 
Miltenyi Biotec Inc, Auburn, CA USA). Enriched T cells were labeled with 
fluorescent Abs: anti-CD8 PerCP, anti-CD45RO PE, and anti-CD62L FITC (all 
purchased from BD Biosciences, CA, USA).  T cell populations representing TCM 
and TEM were gated and sorted on a BD FACS Aria-II SORT (BD Biosciences, CA, 
USA) based on the following markers: TCM as CD8+CD45RO+CD62L+ and TEM 
populations as CD8+CD45RO+CD62L−. Single cell sorted T cells were replated at 1 
cells/well in 96-well round-bottom plates with 2 × 104 γ-irradiated HLA A0201+,  
CMVpp65+ AAPCs, 5 × 105 γ-irradiated autologous peptide-pulsed PBMCs and 2 × 
105 γ-irradiated BLCLs as feeders in T cell media with 50 U/ml IL-2 and 25ng/ml IL-
15.  T cell were cultured in Yssel’s medium with 15% heat inactivated human 
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serum (Gemini, CA, USA) in humidified incubators at 37C and 5% CO2. 
Flow cytometry phenotypic analysis  
T cell clones were analyzed by flow cytometry after staining with fluorochrome-
conjugated mAbs to CD3, CD8, CD62L, and CD45RA. Commercially available 
CMVpp65 MHC-peptide tetramers for HLA-A 0201-bearing peptide sequences 
NLVPMVATV (Beckman Coulter) were used. Functional activity of T cells was 
evaluated after short secondary stimulation by several parameters including T 
cell generation of intracellular cytokines (IFN-γ, TNF-α and IL-2) as quantified by 
intracellular fluorescence staining. Briefly, irradiated autologous BLCLs loaded 
with NLVPMVATV peptide were co-incubated with T cells at an effector to target 
ratio of 1:5 for 6 hours in the presence of 1 μg/ml brefeldin A (Sigma-Aldrich, MO, 
USA). Co-cultured T cells were then labelled with anti-CD3 APC and anti CD8 
PE for 15 mins at room temp, washed and then permeabilized with Perm solution 
(BD Biosciences). There were then co-incubated with anti-IFN-γ PE (BD 
Biosciences) and anti-TNF-α APC (Miltenyi Biotec), or anti-IL-2 FITC (BD 
Biosciences). Samples were analyzed on a FACSCalibur using CellQuest 
Software (BD). 
 
Characterization of CMV-specific T cell clones by quantitative analysis of TCRV
β repertoire 
CMV peptide-HLA tetramer+ T cells were analyzed for their TCRVβ repertoire 
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via flow cytometry using a commercially available kit containing antibodies to 24 
subfamilies of the Vβ region of the human TCR (IO Test β Mark; Beckman 
Coulter) according to procedures provided by the manufacturer (24). 
Cytotoxicity of CMV-specific CTLs by in vitro cytotoxicity assays 
T cells clones were assessed for their capacity to lyse CMVpp65-loaded targets 
using a standard 51Cr release assay as previously described (25). Targets were 
autologous EBV-BLCL alone, and EBV-BLCL pulsed with CMVpp65 peptide 
nonamer NLVPMVATV at a T cell: BLCL ratio, 1:1 or 10:1. 
Bioluminescent labeled CMV-specific T cell lines  
Sort-purified CD8+CD45RO+CD62L+ TCM and CD8+CD45RO+CD62L- TEM cells 
were cocultured with 1 × 105 γ-irradiated HLA A0201+, CMVpp65+ AAPCs and 1 × 
105 γ-irradiated autologous peptide-pulsed PBMCs per 106 of T cells. On day 4, 
cells were transduced with retrovirus supernatant carrying the extRLuc construct 
as previously described (26). This vector introduces genes directing the expression 
of two reporters, a membrane-anchored form of the Gaussia luciferase enzyme 
(extGLuc) and green fluorescent protein. T cells were cultured with the extGLuc 
retrovirus supernatant together with 1 × 105 γ-irradiated mouse pro-B cell Baf-3 
cells transduced to express the IL-15Rα and IL-15 genes (BAF3 IL15/15Rα) (27) 
on retronectin coated plates. Retrovirus transductions were repeated on day 5 and 
day 6. T cell cultures were supplemented with IL-2 (20 U/ml) and 10 ng/mL rhIL-15 
starting on day 12 and then three times per week. Thereafter, cells were re-
stimulated every 10-days with AAPCs and irradiated autologous PBMC feeders. 
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The extGLuc+ T cells were sorted by GFP on a BD FACS Aria-II SORT (BD 
Biosciences, CA, USA) on day 38 and 78. After enrichment by antigen stimulation, 
the CMV pp65-specific extGLuc+ T cells were expanded using a rapid expansion 
method by which 106 T cells were stimulated with 30 ng/mL anti-CD3ϵ (OKT3; 
Ortho Biotech), 5 × 107 γ-irradiated autologous PBMCs, and 107 γ-irradiated 
autologous BLCLs in 50-mL culture media (21). Cultures were then supplemented 
with 50 U/mL IL-2 and 10 ng/mL rhIL-15 every 48 hours. OKT3 expansions of T 
cells were performed on day 53, 71 and 78 to reach enough cell numbers for in 
vivo studies.  
Xenograft models 
In vivo studies utilized six- to 10-week old NOD/Scid IL-2RγC null (NOG) mice. 
Two tumors models were generated by subcutaneous injection of 3 × 105 cells 
from an colon HLA A0201+ carcinoma cell line transduced to express CMVpp65 
(Coca pp65) and an ovarian carcinoma cell line also expressing HLA A0201+ 
(SKOV-A2). The two tumor cells lines were both transduced to express firefly 
luciferase five days before T cell transfer. The growth of these tumors could then 
be imaged by bioluminescence following I.P. injection of luciferin. In the adoptive 
transfer experiment, we injected 1 × 107 TCM or TEM derived extGluc+GFP+ CMV-
specific T cells on day 0 by retro-orbital injection into tumor-bearing NOG mice.  
Irradiated BAF3 IL15/15Rα cells as previously described (27) (1 × 106) were 
administered intraperitoneally once a week starting on day 0 to provide a 
systemic supply of human IL15/15Rα complex in IL-15 treated groups in vivo. In 
IL-2 treated groups, IL-2 was given twice a week (2000U/mice). The mice were 
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then monitored in weight and general health. Tumors were imagined by 
bioluminescence at 0, 7, 14, 21, and 30 days post T-cell infusion. At 40 days, the 
mice were euthanized and autopsied. Tumors, spleen, and liver were examined 
for T-cells by immunohistochemistry. 
Bioluminescence imaging 
Bioluminescence was detected using a Xenogen IVIS Imaging System 
(Xenogen) as previously described (28). We performed imaging of the T cells 
either immediatedly following retro-orbital injection with coelenterazine (250 μg) 
(Nanolight Technology) or tumors 10 mins after intraperitoneal injection of D–
luciferin (150 mg kg) (Xenogen). We imaged mice individually whenever 
coelenterazine substrate was used whereas 5 mice were simultaneously imaged 
in luciferin-based acquisitions. Time of image acquisition was in the range of 0.5 
to 3 min. Field of view of 15, 20, or 25 cm with low, medium, or high binning in an 
open filter was utilized to maximize signal intensity and sensitivity. We obtained 
acquisition of image data sets and measurement of signal intensity through 
region of interest (ROI) analysis using Living Image software (Xenogen), and 
normalized images displayed on each data set according to color intensity. 
Immunohistochemistry 
For in situ expression analysis of T cells, immunohistochemistry analysis was 
performed. Formalin-fixed paraffin-embedded samples of tissue biopsies were 
performed of the Department of Pathology at MSKCC. IHC was performed as 
described previously (29). Briefly, slides were subjected to a heat-based antigen 
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retrieval procedure (30 minutes, 98°C) followed by the application of the first 
primary antibody (CD8 and CD45, DAKO) overnight at 4°C. A biotinylated horse-
anti-mouse secondary antibody (1:200; Vector Laboratories) was used to detect 
the primary antibody, followed by an avidin-biotin-complex system with 
peroxidase as a reporter enzyme (elite ABC kit; Vector Laboratories); 3,3-
diaminobenzidine tetrahydrochloride (liquid DAB; Biogenex) served as 
chromogen for the visualization of CD45 and CD8 expression. Appropriate 
negative controls omitting the primary reagent were included for each case.  
Statistical analysis 
We performed statistical analyses using Prism (GraphPad Software). We used a 
nonparametric Mann-Whitney test to compare two groups between different 
tumor growth. Two-sided p values were used; where indicated in figures signifies 
**p = 0.01 
 
 
 
 
 
 
  
16
	
	
3. Results 
3.1. Characterization of CMV-specific CD8+ T cell clones derived from TCM and 
TEM cell population for adoptive T cell transfer 
Clonally derived CD8+ T cells isolated from central memory T cells are 
functionally distinct from those derived from effector memory T cells in nonhuman 
primates (13). To examine whether this is also the case for antigen-specific 
human T cells, CD8+ CMV-specific T cell clones were isolated from CMV 
seropositive HLA-A 0201+ donors by single cell sorting CD62L+CD45RO+CD8+ 
TCM cells and CD62L-CD45RO+CD8+ TEM cells and then sensitizing the sorted T 
cells with artificial antigen presenting cells (AAPCs) exclusively expressing HLA-
A 0201, CMVpp65 and T cell costimulatory molecules as previously described 
(30), using irradiated autologous PBMCs and BLCLs as feeder cells. (figure 1) 
CD8+ CMV-specific T cell clones derived from TCM and TEM were then isolated 21 
days after in vitro sensitization. CMV antigen specific T cells can be identified by 
NLV-Tetramers, which contain the CMVpp65 epitope NLVPMVATV (NLV) 
enfolded by HLA A0201. That the T-cells were clonal was confirmed by 
evaluating the Vβ usage of Tetramer+ TCM and TEM derived clones. (figure 2) In 
one representative clone, analysis of TCR Vβ chain in the T cell clone derived 
from the TEM cell population revealed a single Vβ13.1 peak. Another T cell clone 
derived from the TCM cell population of the same individual exhibited a single 
Vβ14 peak. Thus, our TCR Vβ repertoire analysis of NLV-Tet+ populations 
provided evidence that CMV-specific T cell clones derived from both TCM and TEM 
population could be generated using our AAPC platform.  
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We then evaluated the phenotype of T cell clones derived from the TCM and TEM 
populations isolated from each donor’s PBMC. After the 21 day expansion, the 
Tetramer+ T cell clones generated from both the TCM and TEM populations 
exhibited a CD62L-CD45RA- TEM phenotype. This is shown in two representative 
clones from both populations in figure 3A (left two: TCM derived clones; right two: 
TEM derived clones).  
We then evaluated the TCM and TEM derived clones at a functional level. We first 
evaluated the capacity of TCM and TEM derived Tet+ clones to secret cytokines 
after antigen stimulation. Accordingly, TCM and TEM derived clones were 
secondarily stimulated for 6 hours with autologous BLCLs loaded with the NLV-
peptide to test for antigen-specific response or with BLCLs loaded with an 
unrelated peptide, RPH as a control. As shown in figure 3B, T cell clones derived 
from either TCM or TEM cell populations had the ability to secrete high levels of the 
cytokines TNF-α and IFN-γ, but not IL-2. T cell clones pulsed with control peptide 
RPH did not secrete cytokines. Thus, the T cell clones we generated from TCM 
and TEM populations secreted cytokines in an antigen-specific manner. We 
further evaluated the cytotoxic activity of TCM and TEM derived clones by 51Cr 
release assay. The cytotoxic activity of the CMV-specific clones was examined at 
an E/T ratio of 10:1 and 1:1 using autologous BLCLs pulsed with NLV peptide as 
target cells. Specific lysis of these target cells was quantitated in comparison to 
lysis of un-pulsed autologous BLCLs as controls. All of the TCM and TEM derived 
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clones could specifically lyse the target cells (figure 3C). Of the 4 clones derived 
from TCM population, 3 exhibited 20-40% specific lysis, and one clone exhibited 
80% specific lysis (left panel). Of four representative TEM derived clones, all 4 
exhibited a similar level of specific lysis, ranging from 40-60% (right panel). No 
Significant differences were observed in the cytotoxicity exhibited by the TCM or 
TEM clones at E/T ratios of 10:1 and 1:1. Thus, based on our functional analysis 
of TCM and TEM derived clones, both TCM and TEM derived clones have a similar 
level of functional ability to secrete cytokine and induce cytotoxcicity in response 
to CMV antigen. Therefore, our data are consistent with those of Berger et al. 
(13) in that CMVpp65 specific T-cell clones derived from TCM and TEM populations 
in the blood after extended in vitro expansion exhibit a TEM phenotype and are 
indistinguishable in their effector function.  
3.2. Evaluation of the persistence, homing capacity and functional properties of 
CMV-specific CD8+ T cell derived from TCM and TEM cell populations following 
adoptive transfer in vivo 
We next wished to examine the acticity of CMV-specific cells derived from TCM 
and TEM populations in vivo. Unfortunately, despite several attempts, we were 
unable to expand T cell clones derived from TCM and TEM to numbers adequate to 
perform the in vivo studies planned. Accordingly, we decided to analyze the 
activity of the full spectrum of CMVpp65-specific memory T cells generated from 
TCM and TEM populations in our in vivo model. To visualize the T-cells in vivo we 
used a modification of a bioluminescence system to image T-cells expressing a 
19
	
	
membrane-anchored form of the Gaussia luciferase (GLuc) enzyme, termed 
extGLuc, previously described by Santos et al. (26). Accordingly, as outlined in 
figure 4, we first sorted CD62L+CD45RO+CD8+ TCM and CD62L-CD45RO+CD8+ 
TEM cell populations from the PBMC of seropositive HLA A0201+ donors and 
sensitized them with the artificial antigen presenting cells (AAPCs) expressing 
HLA-A 0201 and CMVpp65. Four days post stimulation, the T-cells were 
transfected with a retroviral vector encoding extGLuc in the presence of 
irradiated BAF3 cells constitutively expressing IL15/15Rα complex (BAF3- 
IL15/15Rα) at a ratio of 10 T-cells : 1 BAF3-IL15/15Rα cells were added to 
increase the proliferation of the sensitized T cells in order to enhance 
transduction efficiency with the extGLuc vector. To maximize the number and 
concentration of CMV-specific T cells derived from TCM and TEM population 
labeled with extGLuc, we FACS sorted GFP+ cells after 4 rounds of antigen-
stimulation, and further expanded with 2 rounds of sensitization with the 
CMVpp65+ AAPC in the presence of OKT3 (figure 5), this protocol yielded 
sufficient numbers of CMVpp65 Tet+ cells of high purity for the in vivo 
experiments. The phenotypic and functional characteristics of the CMV-specific T 
cells were validated before T cell infusion. The TCM and TEM derived cells 
contained 86% and 89% NLV-Tetramer+ T-cells (figure 6A). As previously shown 
for TCM and TEM derived T cell clones, both TCM and TEM derived GFP+ cells 
exhibited a TEM phenotype before infusion. The level of GFP expressing cells 
was also confirmed in both populations (figure 6A). We also examined the 
capacity of the Tet+ GFP+ T-cells to specifically secrete cytokines in response to 
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antigen stimulation after 78 days of expansion. In vitro expanded GFP+ TCM and 
TEM derived cells were secondarily stimulated for 6 hours with autologous NLV 
peptide loaded BLCLs, and compared to the unpulsed control. Both GFP+ TCM 
and GFP+ TEM derived cells specifically secreted high levels of TNF-α and IFN-γ 
in response to the CMVpp65 peptide (figure 6B).  
For our studies of the T-cells in vivo, we established a human xenograft model in 
NSG mice (IL-2R-γc-KO on NOD/SCID mice), mice which have been described 
as the most permissive hosts for engraftment of human cells and tissues (31). In 
this model, two human tumor xenografts are grown in each mouse, one an HLA 
A0201+ colon carcinoma transduced to express CMVpp65 (Coca pp65), and the 
other an ovarian cancer control tumor expressing HLA-A 0201 (SKOV-A2) but 
not CMVpp65. The expression of HLA-A 0201, CMVpp65, and the co-stimulatory 
molecules ICAM-1, B7.1 and LFA-3 in Coca pp65 and SKOV-A2 are illustrated in 
figure 7A. Compared with an HLA-A 0201 BLCL cell line that expresses high 
levels of HLA-A 0201, ICAM-1, B7.1 and LFA-3, the Coca pp65 and SKOV-A2 
cells express similarly high levels of HLA-A 0201 and ICAM-1, but low levels of 
B7.1. Coca pp65 express high levels of LFA-3 (78%), while SKOV-A2 cells 
express low levels of LFA-3 (21%). The expression of CMVpp65 in the Coca 
pp65 cell line was confirmed by IHC staining using a florescence labeled 
CMVpp65 antibody (figure 7B).  
To assess the in vivo function of TCM and TEM derived CMV-specific T cell 
populations, we subcutaneously injected 0.3 million Coca pp65 cell line in the 
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right thigh and SKOV-A2 tumor cell line in the left flank of each mouse. At day 5, 
we intravenously infused HLA A0201-restricted extGLuc+ CMV-specific TCM or 
TEM derived cells into each mouse. We also injected one group of mice with HLA 
B0702 restricted CMV-specific T cells as a control. To compare the differences 
between IL-2 and IL-15 treatment, groups of mice were treated with recombinant 
IL-2 protein (2000U per mouse two times a week) or irradiated BAF3-IL15/15Rα 
cell line alone. The model and the treatment groups are summarized in figure 11. 
The level of IL-15 concentration maintained in mouse serum ranged between 
100-400 pg/ml in each mouse. Bioluminescent imaging was performed by 
infusing coelenterazine as the substrate of extGLuc to detect T cell signal, and 
luciferin as the substrate of luciferase to detect tumor cell growth.  
We first compared the accumulation of T cells from TCM and TEM derived cells in 
IL-2 treated mice. We observed that after infusion, CMV-specific TCM and TEM 
derived cells were initially detected in the lungs (Day 0 figure 9A). T cells in both 
populations started to be detected in the spleen from day 3. At no time were they 
detected in the SKOV-A2 tumor. However, by day 7, T cells from both 
populations selectively accumulated in the Coca pp65 xenograft expressing 
CMVpp65. This accumulation in the targeted tumor was transient. Indeed, we 
failed to detect T cells at the CMVpp65+ tumor site by day 21 (figure 9A). In 
contrast, we detected a different kinetics and distribution of T cells in mice co-
treated with the irradiated BAF3-IL15/15Rα cell line. While the accumulation of 
both TCM and TEM were again detected only in the Coca pp65 xenograft, TCM 
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derived T cells accumulated later: by day 14 in one mouse and day 21 in the 
other 3 representative mice. In contrast,  TEM derived T cells accumulated at 
tumor expressing CMVpp65 earlier, by day 7 in one mouse and day 14 in the 
other 3 in 4 representative mice (figure 9B). Furthermore, in contrast to the mice 
treated with IL-2, by day 31, T cells also began to accumulate to the bone 
marrow (figure 9B).  
To compare the T cell accumulation at antigen-bearing tumor sites, we 
performed quantitative analysis of the bioluminescence signal at the indicated 
time points, comparing CMV-specific TCM and TEM derived cells in both IL-2 and 
IL-15 treated mice. In vivo T cell bioluminescent signals were quantified by 
photons/sec to evaluate the total flux on the different days post transfer. Results 
are presented in Figure 9C. In mice treated with IL-2, both TCM and TEM derived 
cells peaked in their accumulation at the Coca pp65 tumor site on day 7 and 
were detected only in TEM treated mice by day 14. Accumulation of TCM and TEM 
derived cells, did not differ significantly in IL-2 treated mice (figure 9C: upper 
panel). In mice treated with irradiated BAF3-IL15/15Rα cell line, TCM derived cells 
achieved a greater accumulation of T cells at the Coca pp65 tumor site 
compared to TEM derived cells (figure 9C: lower panel). Mice treated with 
irradiated BAF3-IL15/15Rα cell also sustained the accumulation of TCM cells in 
these tumors through 21 days and TEM through 14 days thus providing evidence 
that L15/15Rα treatment also enhanced CMV-specific T cell persistence at the 
targeted tumor site when compared to IL-2. (figure 9C) Our experiments thus 
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showed that both TCM and, to a lesser degree TEM CMV-specific CD8 T cells 
persisted longer at the targeted tumor sites in IL-15 treated mice. 
To evaluate the in vivo function of CMV-specific TCM and TEM derived cells, we 
next quantified the tumor growth by total flux and converted to the percentage of 
tumor growth post transfer to evaluate the antitumor activity of the T-cells and 
cytokines in different treatment groups. In IL-2 treated mice, we failed to show 
any differences in the growth of Coca pp65 tumors with or without when treated 
TCM or TEM derived cells or with CMVpp65 specific HLA B0702 restricted, the 
negative control (figure 10A). On the other hand, in growth of the Cocapp65 
tumors in mice treated with irradiated BAF3-IL15/15Rα cells together with either 
TCM or TEM derived cells was significantly inhibited compared to mice treated with 
the BAF3-IL15/15-Rα cells alone (figure 10C; **p= 0.01). There were no 
differences observed on the growth of the SKOV-A2 tumors with or without T cell 
transfer in either the IL-2 or the IL-15 treated mice (figure 10B and D). 
We next evaluated the persistence of detectable CMV-specific human T cells in 
the spleen, the tumors and the bone marrow of mice bearing the human tumor 
xenografts by FACS analysis of single cell suspension obtained at autopsy 45 
days post treatment. Consistent with our bioluminescent imaging results at day 
31, we failed to detect human CD8+CD45+ T-cells in the spleen from mice treated 
with either TCM or TEM derived cells irrespective of whether they were treated with 
IL-2 or IL-15 (figure 11 A and B). For each treatment group one representative 
graph is presented in the upper panel. The human CD8 T cell frequencies in all 
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of the mice in each group are presented in the lower panel (n=6).  
We attempted to make single cell suspensions for the tumors. However, 
homogenization of the tumor xenografts, unlike the spleen, yielded mucinous 
debasing preventing separation of cell suspensions appropriate for FACS. 
However, each of the tumors was submitted to immune histology evaluation. 
While human T-cells were detected selectively in the Caco pp65 xenografts, as 
shown in Figure 12E, they were rare. These findings are consistent with the 
results of the bioluminescence imaging since, by day 31, accumulation of neither 
TCM nor TEM could be detected in the Coca pp65 tumors. In contrast to the spleen 
and Coca pp65 tumors, but consistent with our bioluminescent imaging, we did 
identify CD8+CD45+ human CD8 T cells from both TCM and TEM derived cells in 
the bone marrow of mice co-treated with IL-15/IL-15Rα (figure 12 A and B). In 
contrast, we failed to detect either TCM or TEM derived T cells in the marrow of 
mice co-treated with IL-2. In addition, we did not find human T-cells in mice 
treated with the control CMVpp65-specific, HLA B0702 restricted T-cells. These 
results not only provide evidence that IL-15/IL-15Rα compared to IL-2, can 
prolong T cell persistence, but also indicate that the human TCM and TEM T cells 
preferentially accumulate and can persist in the bone marrow after population of 
T-cells accumulated in the targeted tumors have dissipated. 
We also examined whether the TCM and TEM derived cells persisting in the 
marrow exhibited phenotypic and/or functional differences from these infused at 
the time of adoptive transfer into NSG mice. Accordingly, we extracted T cells 
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from the bone marrow of mice sacrificed 45 days post transfer that had been 
treated with irradiated BAF3-IL15/15Rα cells. Phenotypic analysis was performed 
gated on CD8+CD45+ human CD8 T cell populations. As shown in figure 12C, 
both TCM and TEM derived cells have the same CD62L-CD45RA-CCR7-CD127- 
effector cell phenotype and are not different from those initially infused. We also 
evaluated whether the T-cells in the marrow of the NSG mice extracted from 
bone marrow after engraftment for 45 days are functional. Accordingly, we re-
challenged these T-cells with autologous BLCL pulsed with NLV-peptide. IFN- γ 
secretion and BrdU assays were performed to evaluate T cell proliferation and 
effector function in the presence or absence of CMVpp65 peptide stimulation. As 
shown in figure 12I, from one representative mouse, 46% of CD8+CD45+ human 
TE cells secreted IFN-γ in response to CMVpp65 peptide loaded BLCL compared 
to 0.4% of the T-cells stimulated with BLCLs alone. Similarly, after secondary 
challenge with NLV-peptide pulsed BLCLs 14.3% of the T-cells were BrdU+ 
compared to 9.3% of T-cells pulsed with BLCLs alone (figure 12J). These results 
indicate that T cells persisting in the bone marrow are functional and exhibit 
antigen-specific IFN-γ production and T cell proliferation. To further evaluate the 
effects of IL-15/IL-15Rα, we also evaluated the relative expression of IL-15Rα in 
these TCM and TEM derived TE cells. Cells in the CD8+CD45+ gated population 
exhibited a higher level of IL-15Rα expressing cells in TCM compared to TEM 
derived cells (TCM: 4.5%; TEM: 0.8% figure 12H). This result is consistent with 
previous findings in a nonhuman primate model that the TCM but not TEM derived 
clones expressed higher levels of IL-15Rα (13). That study suggested that the 
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superior persistence of TCM derived cells was due to their higher expression of IL-
15Rα (13). Our data suggest that the higher expression level of IL-15Rα in TCM 
derived cells might also explain the greater accumulation of TCM derived cells at 
the targeted Coca pp65 tumor site compared to TEM derived cells.  
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4. Discussion 
The characteristics of antigen-specific memory T-cells have been postulated to 
be major determinants of the persistence of transferred cells and correlates of 
therapeutic efficacy. Previous studies by Berger et al. (13) of autologous CMV-
specific T-cells in macaques have demonstrated that CD8+ effector T cells 
derived from macaque CD62L+CD95+ TCM precursors, retain the capacity to 
engraft and reconstitute functional memory upon adoptive transfer, whereas 
effectors derived from CD62L− TEM precursors do not. In a subsequent study 
from the same group, Wang et al. (21) adoptively transferred human CMV pp65-
specific T-cells generated from the CD8+CD45RO+CD62L+ TCM or 
CD8+CD45RO+CD62L- TEM fractions of PBMCs derived from seropositive donors 
into NSG mice, and observed that while both fractions were able to achieve 
engraftment, the TCM derived cells engrafted to a markedly greater extent, and 
that the TE derived from these cells exhibited greater diversity, secreted higher 
levels of IL-2 and were able to prevent outgrowths of intravenously administered 
autologous EBV transformed BLCL transduced to express CMVpp65. While both 
TCM and TEM derived TE cells proliferated in vivo, a significantly higher proportion 
of TEM derived T-cells underwent apoptosis. Furthermore, in their model, growth 
of both TCM and TEM derived T-cells were sustained only in NSG mice that also 
received twice weekly intraperitoneal injections of irradiated murine NSO 
myeloma cells transduced to express human IL-15 such that the mice were able 
to maintain IL-15 levels of 6-8 pg/ml. From these experiments, they concluded 
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that while both TCM and TEM derived T-cells were dependent on IL-15, TCM derived 
T-cells had a markedly greater potential of sustained survival and were therefore 
more likely to provide sustained, antigen-specific function. 
In our study, we wished to further define conditions and attributes of CMV-
specific T-cells that contributed to their activity against human cells that are 
actually targets of CMV infection, and to compare TCM and TEM cells under these 
conditions for their capacity to achieve sustained engraftment, selectively 
accumulate in sites of antigen expression, and inhibit or eradiate cells expressing 
the targeted CMV antigen. Accordingly, we developed a human xenograft model 
in NSG mice in which the mice bear two human carcinomas with similar growth 
characteristics, both selectively expressing class I HLA A0201, and one, a colon 
carcinoma line, also transduced to express CMVpp65. The colon carcinoma was 
chosen because it, like normal colonic epithelium, but unlike human B cells, is 
naturally susceptible to productive infection by CMV. Indeed, CMV colitis is a 
significant cause of morbidity and mortality in transplant recipients and other 
immunocompromised patients. In addition, transduction of the tumor cells to 
express firefly luciferase permitted sequential evaluations of the growth of the 
CMVpp65+ and CMVpp65- xenografts in vivo. In order to contemporaneously 
delineate the homing characteristics of the transferred T-cells and distinguish 
their effects on targeted CMVpp65+ tumor xenografts, we transduced the TCM and 
TEM derived CMVpp65-specific T-cells to express both GFP and a Gaussia 
luciferase which employs a different substrate, coelenterazine, and emits a 
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different light spectrum in bioluminescence imaging. 
An initial important finding of our study was that human CMV-specific CD8+ T 
cells derived from TCM and TEM exhibit superior engraftment in IL15/15Rα treated 
mice compared to IL-2 treated mice. This result extends the findings of Wang et 
al. (21), who found that the IL-15 provided by irradiated IL-15 providing NSO cells 
was required for sustained in vivo engraftment and survival of transferred human 
antigen-specific T cells. However, in contrast to their findings that antigen-
specific CD8+ T-cell clones derived from TCM, but not TEM, were capable of 
engrafting long-term, we failed to show a significant difference in the long-term 
engraftment of T cells derived from TCM and TEM. We did observe, however, that 
TCM derived CMVpp65+ specific T-cells selectively accumulated in the CoCa 
CMVpp65+ tumors to a much greater degree and for a longer interval than TEM 
derived CMVpp65+ specific T-cells. However, despite the differences in 
accumulation in the CoCapp65+ tumors, the TCM and TEM derived T-cells induced 
an almost identical degree of suppression of the growth of these tumors. 
Furthermore, the absence of any accumulation of T-cells in or inhibition of the 
growth of the SKOV-A2 tumors suggests that neither the TCM nor the TEM derived 
CMVpp65-specific T-cells exert an antigen-nonspecific effect. 
A striking characteristic of both TCM and TEM derived CMVpp65 specific T-cells in 
this model was their long term persistence in the bone marrow of NSG mice that 
received injections of the irradiated BAF-3 cells secreting IL-15 and IL-15/IL-
15Rα complex. Similar to the findings of Wang el al. (21) in mice that did not 
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receive IL-15 secreting cell supplementation, neither TCM derived nor TEM derived 
T-cells were detected in the marrow of mice treated with IL-2. Unlike the findings 
of Wang et al. (21) in mice treated with NSO cells secreting IL-15 alone, the 
levels of TCM and TEM derived T-cells that persisted in the marrow of our mice 
were not significantly different. However, in agreement with their findings, we 
found that the T-cells in the marrow consisted exclusively of TEM and TE T-cells. 
We did not detect any T-cells exhibiting a CD45RO+CD62L+CCR7+ TCM 
phenotype as has been described in primates infused with autologous CMV-
specific TEM and TE cells generated from TCM precursors in the blood. We did, 
however, observe that the TCM -derived TE cells persisting in the marrow differed 
from TEM -derived TE cells in that a proportion of these TE cells expressed IL-
15Rα, a finding also reported by Berger et al. (13) for TCM derived T-cells that 
persist long-term in non-human primates. The TCM-derived TE cells in the marrow 
were also able to proliferate and to generate IFN-γ in response to CMVpp65 
peptide indicating their functional competence. 
Taken together, our studies indicate that while TCM and TEM derived T-cells 
exhibited differences in phenotype and in the kinetics and degree of their 
respective accumulations in CMVpp65+ CoCa xenografts, their antigen-specific 
activities and their persistence in vivo were equivalent. The differences between 
our findings and those of Wang et al. (21) principally hinge on the limited levels of 
engraftment and persistence of TEM derived T-cells in the marrow that they 
observed, attributes that they ascribed to the markedly increased level of 
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apoptosis detected in the TEM derived T-cell populations even early after antigen-
stimulation. While multiple factors may contribute to this disparity in results, one 
clear possibility is that in our model, the NSG mice received regular injections of 
irradiated BAF-3 cells generating both human IL-15 and IL-15Rα while the NSG 
mice in the studies of Wang et al. (21) received injections of irradiated NSO cells 
secreting human IL-15 alone. The levels of IL-15 thereby sustained in the blood 
of the mice were markedly different, ranging from 100 to 400 pg/ml blood in the 
mice receiving the BAF3 cells secreting IL-15 and IL-15Rα compared to 4-6 
pg/ml in the mice treated with the NSO cells secreting IL-15. Furthermore, since 
IL-15/IL-15Rα are also secreted and can act in trans (32), they may provide an 
adequate stimulus to the TEM derived T-cells to enhance and sustain their 
survival and function. This mechanism may also, in part, explain why, in both 
models, the bone marrow is the only site where significant populations of 
CMVpp65-specific TEM derived T-cells are detected, since antigen-specific 
memory CD8+ T-cells have been shown to receive proliferative signals from IL-15 
secreting cells in the marrow (33), and in human bone marrow, cells expressing 
IL-15R can trans-present IL-15 on their surface (32). 
A unique finding in our study is the disparity between the transient accumulations 
of the CMVpp65-specific TCM and TEM in the Cocapp65 xenografts in the mice co-
treated with IL-15/IL-15R and their persistence in the marrow of the same mice 
for more than 14 days after accumulation of T-cell in the tumors had decreased 
to levels no longer imaginable. The fact that the TCM and TEM derived T-cells 
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isolated from the marrow retained their capacity to generate cytokines and lyse 
targets co-expressing the NLV peptide and its presenting HLA A0201 allele 
indicates that the T-cells persisting in the marrow are not tolerized. Rather, it 
suggests either that these T-cells never migrated to the tumor xenograft, or, if 
they did, subsequently emigrated to the marrow seeking either a less inhibiting or 
more supportive microenvironment than that provided by the former xenograft. 
In summary, our comparisons of CMV-specific TCM and TEM derived cells, both as 
T-cell clones studied in vitro and as polyclonal CMVpp65-specific T-cell in vivo 
have shown that TCM and TEM derived cells exhibit a similar effector memory 
phenotype as determined by CD62L and CD45RA expression level. In vitro, both 
TCM and TEM clonal populations exhibit comparable HLA-restricted cytotoxic 
activity against CMVpp65+ target cells and secretion of high levels of IFN-γ and 
TNF-α, but not IL-2. In NSG mice bearing CMVpp65+ and CMVpp65- HLA 
A0201+ human tumor grafts that are also treated with irradiated IL-15 and IL-
15Rα secreting cells (but not in mice treated with IL-2), both TCM and TEM derived 
T cells selectively but transiently accumulate in the tumors coexpressing 
CMVpp65 and HLA A0201, induce an equivalent degree of inhibition of the 
growth of these tumors and thereafter, either die off or leave the tumor site by 31 
days persist at similar levels in the marrow for at least 45 days post infusion. The 
differences we found lie in the greater and more prolonged accumulation of TCM 
derived cells at CMVpp65+ tumor sites compared to TEM derived cells in the IL-
15/IL-15Rα treated mice. Whether and to what degree these findings reflect the 
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higher level of IL-15Rα expression observed in TCM derived cells or other 
signaling molecules promoting their more sustained accumulation in targeted 
tumors remain to be determined.  
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Figure 1.   
Experimental design for isolation and expansion of human CMV-specific CD8 T 
cell clones from TCM and TEM population 
T cell populations representing TCM and TEM were gated and sorted based on the 
following markers: TCM as CD8+CD45RO+CD62L+ and TEM populations as 
CD8+CD45RO+CD62L−. Single cell sorted T cells were replated at 1 cells/well in 96-well 
round-bottom plates with 2 × 104 γ-irradiated HLA A0201+, CMVpp65+ AAPCs, 5 × 105 
γ-irradiated autologous peptide-pulsed PBMCs and 2 × 105 γ-irradiated BLCLs in T cell 
media with 50 U/ml IL-2 and 25ng/ml recombinant IL-15. 
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Figure 2.  
TCM and TEM derived clonal population were confirmed by TCR Vβ repertoire 
analysis 
TCR Vβ repertoire analyses were shown from one of the representative clones from 
both TCM and TEM derived cells. Each bar graph represents the TCR Vβ usage from TEM 
and TCM derived cells. TEM derived clone 58 revealed a single Vβ13.1 peak (upper 
graph), whereas TCM derived clone 25 from the same individual exhibited a single Vβ14 
peak (lower graph). 
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Figure 3.  
Phenotypic and functional characterization of TCM and TEM derived CMV-specific 
CD8 T cell clones 
(A) T cell clones derived from the TCM (clone 12 and clone 15; Left 2 lanes) and TEM 
(clone 46 and clone 66; Right 2 lanes) populations isolated from the same donor. HLA-
A2-NLV tetramer binding gated on CD8 T cells was confirmed in each TCM and TEM 
derived clones (upper graph). Expression of CD62L and CD45RA on individual TCM- 
and TEM-derived clones was evaluated (lower graph). The data were from two 
representative clones in each population. (B) Expanded T cell clones derived from TCM 
(left lane) and TEM (middle lane) were stimulated for 6 hours with NLVPMVATC (NLV) 
peptide loaded autologous BLCLs at a ratio of 5:1 from one representative clone. T-cells 
co-cultures with autologous BLCLs with unrelated peptide RPH loaded autologous 
BLCLs served as controls (right lane). Cytokine secretion of TCM and TEM derived clones 
were evaluated by intracellular staining within T cell clones using anti-IFN-γ, anti-TNF-α, 
and anti-IL-2 antibody. (C) Cytotoxic activity of TCM-derived (left panel) and TEM-derived 
clones (right panel) were examined at an effector-to-target ratio (E/T ratio) of 1:1 and 
10:1 using autologous BLCLs loaded with or without NLV-peptide as target cells. 
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Figure	3	(Continued)	
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Figure 4. 
Experimental design for generation of genetically modified CMV-specific T cells 
expressing reporters for bioluminescent imaging in vivo 
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Figure 5.  
Schematic of the methods for generating CMVpp65 specific T cells transduced to 
express extGLuc 
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Figure 6.  
Phenotypic and functional characterization of bioluminescent-labeled TCM and TEM 
derived CMV-specific CD8 T cell lines 
(A) Phenotypic analysis of extGLuc+ T cell lines derived from the TCM and TEM 
populations expanded for 92 days. HLA-A2-NLV tetramer binding gated on CD8 T cells 
was confirmed in TCM and TEM derived cells. Retrovirus transduced to express extGLuc 
was confirmed by GFP expression. Expression of CD62L and CD45RA on individual 
TCM- and TEM-derived clones was evaluated (lower graph). (B) Cytokine secretion of T 
cell population derived from TCM and TEM expanded for 78 days. T cells derived from 
TCM (middle lane) and TEM (middle lane) were stimulated for 6 hours with NLVPMVATC 
(NLV) peptide loaded autologous BLCLs at a ratio of 5:1. T-cells co-cultures with 
unpulsed autologous BLCLs served as controls (left lane). CD8+ T-cells secreting IFN-γ 
and TNF-α were evaluated by intracellular staining. 
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Figure	6	(Continued)	
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Figure 7.  
Expression level of costimulatory molecules in different cell lines 
(A) Level of costimulatory molecules expression, including HLA-A2, ICAM-1, B7.1 and 
LFA-3 on tumor lines (SKOV-A2: middle lane; Coca pp65: right lane) compared to 
BLCLs (left lane) were evaluated by flow cytometry. (B) Coca tumor cell line transduced 
to express CMV antigen pp65 was confirmed by IHC staining. 
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Figure 8 – 
Experimental design of bioluminescent imaging for tumor and T cell engraftment 
in different combination treatment of CMV-specific T cells and cytokines in vivo 
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Figure 9.  
In vivo comparison of TCM and TEM derived CMV-specific T cell bioluminescent 
signaling in a xenograft tumor model 
NOG mice injected with T cells expressing extGLuc imaged by bioluminescent imaging 
on day 0, 3, 7, 14, 21 and 31 after intravenous injection of coelenterazine. (A) TCM (left 
panel) and TEM (right panel) derived CMV-specific T cell engraftment in IL-2 treated 
mice. Strong T cell signal detected at Coca pp65 tumor on day 7 (red circle) (n=6) (B) 
TCM (left panel) and TEM (right panel) derived CMV-specific T cell engraftment in mice 
treated with irradiated BAF3 IL15/15Rα cells. T cell accumulated at tumor sites in 
different mice (red circle).  T cell accumulated in bone marrow in different mice (yellow 
arrow) (n=6). 4 out of 5 mice imaging have shown in (A) and (B). (C) Quantitative 
analysis of signal at the indicated time points. T cell accumulated at Cocapp65 tumor in 
TCM (black) and TEM (red) derived CMV specific T cells in comparison to IL-2 treated 
(upper graph) or IL15/15Rα treated mice (lower graph) (n=6). 
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Figure	9	(Continued)	
(B)	
	
	
	
	
	
	 	
55
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Figure 10.  
Adoptively transferred CMV-specific CD8 T cells exhibit superior protection from 
tumor growth in IL-15 treated mice 
To assess the in vivo function of CMV-specific T cells derived from TCM and TEM 
populations, quantitative analysis of tumor growth signals at different dates post transfer 
were evaluated in Coca pp65 (A and C) and SKOV-A2 (B and D) tumors. (n=6 in each 
group) NOG mice adoptively transfered with T cells in comparison of mice treated with 
IL-2 or irradiated BAF3 IL15/15Rα cells. Unrelated HLA 0702 CMV-specific T cells 
served as control (Gp7) (n=6). Engraftment of Luciferase expressing Coca pp65 and 
SKOV-A2 tumors were determined by Xenogen imaging. Total flux levels of luciferase 
activity were depicted for each group. (**p=0.01 by Mann-Whitney test) 
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Figure 11.  
TCM and TEM derived CMV-specific T cell engraft in the spleen were not detected 
TCM and TEM derived CMV-specific T cell engrafted in the spleen were determined by 
flow cytometry. (n=6 in each group) (A) Flow cytometry analysis was shown from one 
representative mouse in each group. Human CD8 T cells in the spleen (CD8+CD45+) 
were evaluated in mice treated with IL-2 (left two graphs) or irradiated BAF3 IL15/15Rα 
cells (right two graphs). Percentage of human CD8 T cell frequencies summarized in (B) 
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Figure 12. 
 IL-15 dependent engraftment of phenotypic and functional characterization of 
TCM and TEM derived CMV-specific CD8 T cell lines in the bone marrow 
TCM and TEM derived CMV-specific T cell engrafted in the bone marrow 45 days post 
transfer were determined by flow cytometry. (n=6 in each group) (A) Flow cytometry 
analysis was shown from one representative mouse in each group. Human CD8 T cells 
in the bone marrow (CD8+CD45+) were evaluated in mice treated with IL-2 or irradiated 
BAF3 IL15/15Rα cells. Percentage of human CD8 T cell frequencies summarized in (B). 
TCM and TEM derived CMV-specific T cell engrafted in the bone marrow (C), Spleen (D), 
Coca pp65 tumor(E) and SKOV-A2 (F) were evaluated in mice treated with irradiated 
BAF3 IL15/15Rα cells by immunohistochemistry staining. CD8 staining positive was 
detected in bone marrow and Coca pp65 tumor (C and E). No positive signal was 
detected in Spleen and SKOV-A2 tumor (D and F). (G) and (H) Engrafted T cell 
phenotype derived from TCM and TEM population in IL-15 treated mice. Ex vivo 
expression of CD62L, CD45RA, CCR7, CD127, IL15Rα and CD132 on TCM- and TEM-
derived CMV-specific CD8 T cell gated on human CD8 T cells (CD8+CD45+) was 
evaluated. The data was from one representative mouse in each population. (I) and (J) 
Engrafted T cells are functional in IL-15 treated mice. T cells were stimulated ex vivo 
with NLVPMVATC (NLV) peptide loaded autologous BLCLs at a ratio of 5:1 from one 
representative mice. T-cells co-cultures without peptide loaded as controls. (I) Cytokine 
secretion of T cells was evaluated by intracellular staining using anti-IFN-γ. (J) T cell 
proliferation was evaluated by BrdU assay. 
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Figure	12	(Continued)	
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CHAPTER TWO 
Stem cell-like memory T cells (TSCM) rapidly repopulate circulating virus-
specific effector T cells 
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1. Introduction  
The characteristics of T cells that are selected for expansion and adoptive 
transfer have been identified as a critical factor that determines the efficacy and 
persistence of transferred cells. Antigen-specific T cells responding to infections 
can expand and differentiate into effector T cells, devoted to rapidly clearing the 
pathogens, as well as memory T cells that can persist long-term and defend 
against recurrence of disease. The memory T cell compartment is 
heterogeneous and encompasses multiple subsets with distinctive properties. 
Current evidence indicates that central memory T cells (TCM cells) that express 
high levels of CD62L and CCR7 are less differentiated, while CD62L−CCR7− 
effector memory T-cells (TEM cells) represent committed progenitor cells that 
undergo terminal differentiation (13). Furthermore, studies in mice and 
nonhuman primates have shown that infusion of T cells derived from TCM 
populations exhibit greater replicative potential in response to antigen, and 
prolonged in vivo persistence compared with those derived from the TEM 
population (13, 21). Recently, the spectrum of immunological memory has been 
extended with the identification of stem cell-like memory T cells (TSCM cells) that 
express CD45RA, CCR7 and CD62L like naive T cells, but also express CD95. 
Human TSCM cells have been expanded in vitro (16, 34). When compared with 
other memory T cell populations, human TSCM cells have exhibited increased 
proliferative capacity. TSCM transduced to express a mesothelin-specific chimeric 
antigen receptor have also exhibited greater proliferation and superior antitumor 
responses following adoptive transfer in a humanized mouse model. (16) While 
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TSCM can differentiate into TCM, TEM and effector T cells, they also have a marked 
potential for self-renewal as shown by serial transplantation experiments. (34) 
Because of these attributes, TSCM have attracted considerable interest as a 
critical source of antigen-specific T cells for reconstituting immunity following 
human allogeneic hematopoietic cell transplants (allo HCT). (34-37) Indeed, 
analysis of T cell receptor CDR3 sequences have shown that TSCM undergo 
marked proliferation and clonal diversification early after allo HCT. (37, 38) 
Furthermore, TSCM clones, distinguished by sites of retroviral vector insertion, 
may persist in humans for up to 12 years post infusion.  (36) While these studies 
have underscored the potential of TSCM as a class of memory T cells, both for 
transplantation and adoptive cell therapy, the low frequency of antigen-specific 
TSCM cells has limited their detailed characterization in humans.  (39) 
Furthermore, the contribution of different memory subsets to the maintenance of 
the overall memory compartment of antigen-specific T cells has not been fully 
elucidated.  
In the previous chapter, we have evaluated the differences in their function or 
persistence between TCM and TEM derived T cells in vitro but failed to show a 
significant difference when adoptively transduced into NSG mice bearing human 
tumor xenografts expressing their targeted antigen in vivo. In this chapter, we 
sought to examine the newly characterized TSCM cells and conducted a full 
spectrum, side-by-side comparison of TSCM with other memory subsets. 
Accordingly, we have evaluated human CMVpp65-specific TSCM cells from 
normal CMV seropositive donors comparing their in vitro responses to antigen to 
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those of CMV-specific TCM and TEM as well as to antigen-specific naïve T cells 
(TN). These studies have identified phenotypic and functional features induced by 
antigen stimulation that are common to all memory subsets, as well as 
characteristics of TSCM that distinguish this subset of memory T cells as a 
reservoir for rapid replenishment of immunodominant TEM and TCM in the 
circulation. 
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2. Materials and Methods  
Donors 
Blood samples were obtained from 12 healthy volunteer HLA-A0201+ CMV-
seropositive donors. High resolution HLA typing was performed by analysis of 
HLA allele-specific nucleotide sequences using standard high-resolution typing 
techniques CMV serostatus was determined by standard serologic techniques in 
the clinical microbiology laboratory at Memorial Sloan-Kettering Cancer Center.  
Generation of CMV-specific T cells 
PBMC were isolated from whole blood by Ficoll-Hypaque density gradient 
separation (Accurate Chemical & Scientific Corporation, Westbury, NY USA), from 
which T cells were enriched by depletion of CD19+, CD14+, and CD56+ cells, using 
mAb-coated immunomagnetic beads (Pan T-Cell Isolation Kit II, Miltenyi Biotec 
Inc, Auburn, CA USA). Enriched T cells were labeled with fluorescent Abs: anti-
CD3 PerCP, anti-CD45RO PE, anti-CD95 APC, anti-CD62L FITC (all purchased 
from BD Biosciences, CA, USA), and anti-CD45RA (eBiosciences, CA, USA).  T 
cell populations representing TN, TSCM, TCM and TEM were gated and sorted on a 
BD FACS Aria-II SORT (BD Biosciences, CA, USA) based on the following 
markers: TSCM as CD3+CD45RO−CD62L+CD95+, TN as 
D3+CD45RO−CD62L+CD95−, and the TCM and TEM populations as 
CD3+CD45RO+CD62L+ and CD3+CD45RO+CD62L− respectively. Sorted T cell 
subsets (1x106) were then sensitized with irradiated HLA A0201+ and CMVpp65+ 
AAPCs (0.1x106) as previously described (30) and were additionally cultured in the 
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presence of irradiated autologous PBMCs (2x106) as feeder cells in culture 
medium X-VIVO™ 15 with gentamicin (Lonza, Allendale NJ, USA) and 15% heat 
inactivated human serum (Gemini, CA, USA) in humidified incubators at 37C and 
5% CO2. T cells were supplemented with IL-7 (5 ng/ml), and IL-15 (5 ng/ml) on day 
4 and day 7 after culture initiation and were re- stimulated every 10-days with 
AAPCs and autologous PBMC feeders. After day 12, IL-7 (5 ng/ml), IL-15 (5 
ng/ml), and IL-2 (20U/ml) were supplemented to T cell cultures every other day. 
Quantitation of antigen-specific CD8+ T cells by tetramer analysis 
CMVpp65 specific T cells responsive to the NLV peptide within the cultured T 
cells were enumerated by Tetramer analysis as previously described (30).  
Commercially available CMVpp65 MHC-peptide tetramers for HLA-A 0201 and A 
2402-bearing peptide sequences NLVPMVATV and QYDPVAALF (Beckman 
Coulter) were used. Briefly, T cells were incubated with CD3 FITC, CD8 PE, CD4 
PerCP (BD Biosciences) and an APC-conjugated tetrameric complex for 20 min 
on ice, washed and analyzed by FACS using a FACSCalibur flow cytometer with 
dual laser for four-color capability. Data were analyzed using FlowJo software 
(Tree Star). T cells were gated on CD3- and CD8-positive cells to determine the 
percentage of tetramer-positive CD8 T lymphocytes. 
Phenotypic Analysis of T cell Subsets 
T cell subsets were further characterized by flow cytometry using specific T cell 
memory and co-stimulatory markers.  T cells were labelled with fluorescent 
antibodies against CCR7 PE (BD Biosciences), CD27 FITC (Miltenyi Biotec), 
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CD57 FITC (Miltenyi Biotec), CD127 PE (Miltenyi Biotec), CD28 PECy7 (BD 
Biosciences), KLRG1 PE (Miltenyi Biotec) and PD1 PECy7 (eBioscience), and 
analyzed by FACS. Doublet exclusion for lymphocytes was achieved by gating 
on forward scatter (FSC) vs side scatter followed by FSC (height) versus FSC 
(area).  
Functional characterization of Ag-specific T cells  
Functional activity of T cells was evaluated after short secondary stimulation 
using several parameters including T cells generating intracellular cytokines 
(IFN-γ and TNF-α), activation marker expression (CD137), and cytotoxicity 
(CD107a) by intracellular fluorescence staining. All Abs were purchased from BD 
bioscience. Irradiated autologous BLCLs loaded with NLVPMVATV peptide co-
incubated with T cells in an effector to target ratio of 1:5 for 16 hours in the 
presence of 1 μg/ml brefeldin A (Sigma-Aldrich, MO, USA ). Co-cultured T cells 
were then labelled with anti-CD3 APC and anti CD8 PE for 15 mins at room 
temp, washed and then permeabilized with Perm solution (BD Biosciences) and 
then co-incubated with anti-IFN-γ PECy7 (BD Biosciences) and anti-TNF-α APC 
(Miltenyi Biotec), or anti-CD137 PE (BD Biosciences), or anti-CD107a FITC (BD 
Biosciences). 
Analysis of T cell proliferation and apoptosis 
EdU labeling (ThermoFisher, MA, USA) was used to evaluate T cell proliferation. 
10 μM EdU was added to the culture media for 1h at 37 °C. Labeled cells were 
washed with PBS and resuspended in T cell culture media. T cells were then 
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analyzed by flow cytometry, and the proportion of proliferating T cells was 
determined by the percentage EdU+ gated T cells using the FlowJo software 
(Treestar, CA, USA). Apoptotic T cells were defined by Annexin V staining (BD 
Biosciences). 
TCR next-generation sequencing 
T cell receptor Vβ (TCRVβ) chain hypervariable complementarity-determining 
region 3 (TCRβ CDR3) was amplified and sequenced from DNA extracted from 
NLV-Tet+ T cell subsets (TN, TSCM, TCM, and TEM) isolated by fluorescence-
activated cell sorting (FACS) (purity > 95%) from days 0, 15 or 30 post-
stimulation using the Immuno SEQ platform at Adaptive Biotechnologies (WA, 
USA). Rearranged CDR3 sequences were classified as nonproductive if they 
included insertions or deletions resulting in frameshift or premature stop codons, 
and were excluded from subsequent analyses, according to the Immuno SEQ 
validated algorithm. TCR clonality and sample overlap was determined using the 
Immuno SEQ Analyzer 2.0. wherein, within a range of 0 to 1, a low number 
indicates higher diversity, while a high number indicates higher clonality within 
the sample.  Sample overlap indicates the percent of similar clones within a pair 
of sample types.  
Statistical analysis 
We performed statistical analyses using Prism (GraphPad Software). For most of 
the comparisons we used a nonparametric Mann-Whitney test to compare two 
groups between different populations of the T cells. Within the comparison of 
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Tet+ and Tet- of the same population, we used paired T-test, Wilcoxon signed 
rank test Significance of differences between two groups was calculated using 
the t test (α = 0.05). For all comparisons, two-sided p values were used; where 
indicated in figures signifies *p < 0.05; **p < 0.01, and ***p < 0.001. 
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3. Results 
3.1. Comparison with different cytokine treatments for generating antigen-specific 
human T cells in vitro 
There have been a series of discussions about developing optimal methods of 
antigen-specific priming of human T cells in vitro. Our lab has previously 
developed an in-vitro system for generation of stable 15Rα/15 complexes 
obtained when both IL-15Rα and IL-15 genes were co-transduced in AAPCs. Our 
data suggested that 15Rα/15 complex, but not sIL-15, sustained in-vitro 
expansion of CD62L+ and CCR7+ central memory phenotype cells (27). A 
previous report also showed that requirements for the generation of long-lived 
memory stem cells, described as CD62L+CCR7+CD45RA+CD45R0+IL-
7Rα+CD95+ cells, include CD3/CD28 engagement and culture with IL-7 and IL-15 
(34). It has also been shown that when exposed to IL-21 during primary 
stimulation, central memory type CTL are enriched, in addition, IL-21 also 
maintains the proliferative capacity of antigen-specific T cells, with addition of IL-
7 and IL-15 for robust and strong expansion (40). Accordingly, we performed a 
comparative study to determine which cytokine cocktail would be most effective 
in promoting the growth of antigen-specific T cell populations. We cultured the T-
cells with 7 different combinations of cytokine treatment as well as a non-cytokine 
control, and then quantified the number of antigen-specific cells generated, as 
well as the fold expansion of antigen-specific T-cells observed post culture 
initiation. T cells were stimulated with AAPCs presenting CMVpp65 antigen and 
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HLA A0201. The yield of antigen-specific T-cells was calculated and normalized 
to the number of NLV-Tet+ T-cells present in peripheral blood. The seven 
different sensitizing conditions tested are as follows: 1. AAPC alone. 2. AAPC 
with IL-2. 3. AAPC transduced to express IL-15Rα and IL-15 genes. 4. AAPC 
transduced to express IL-15Rα and IL-15 genes with exogenous IL-2. 5. AAPC 
with recombinant IL-7 and IL-15. 6. AAPC with recombinant IL-7 and IL-15 and 
IL-2. 7. AAPC with recombinant IL-7, IL-15 and IL-21. 8. AAPC with recombinant 
IL-7, IL-15, IL-21 and IL-2. We tested the antigen-specific T-cell number after 7, 
15 and 22 days post-stimulation. The number of antigen-specific cells in millions 
is shown in figure 1A; fold expansion normalized to day 0 is shown in figure 1B.  
The results show that in the presence of IL-7 and IL-15 there is a robust 
expansion of antigen-specific T cell (1300x). IL-2, along with IL-7 and IL-15, 
induces a further T cell expansion (3000x). However, IL-21 shockingly halted T 
cell expansion with (116x) or without IL-2 (105x).  In addition, 15Rα/15 complex 
also promoted T cell expansion to a slightly lower degree than IL-7 and IL-15 with 
(750x) or without (1100x) IL-2. In conclusion, our data provide evidence that 
sensitizing and expansion in the presence of IL-7, IL-15 and IL-2, yield the 
highest number of antigen-specific T cells.  
  
3.2. Detection and isolation of CMVpp65 -specific TSCM cells from healthy 
seropositive donors 
T cells were isolated from peripheral blood mononuclear cells (PBMC) of 12 
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healthy HLA A0201+ CMV seropositive donors.  In each of these CMV-
seropositive donors, we identified TSCM as CD3+CD45RO−CD62L+CD95+, TN as 
CD3+CD45RO−CD62L+CD95−, and TCM and TEM populations as 
CD3+CD45RO+CD62L+ and CD3+CD45RO+CD62L− respectively (fig. 2).  The 
proportion of TSCM cells ranged from 1.2%-10.8% within the T cell populations in 
the peripheral blood in the absence of any in vitro stimulation.  Despite low 
proportions within the PBMCs, we were consistently able to identify the TSCM cells 
in all donors tested (n=12). In comparison, the proportion of TN, TCM and TEM cells 
were 3.8%-28.9%, 1.7%-32.4% and 15.4%-34.9% respectively (table. 1).  
Using CMVpp65 as a model antigen, we then examined the memory phenotype 
of the antigen-specific T cells. Accordingly, we evaluated the CMVpp65-specific 
T cell populations in the blood of 11 of 12 donors. In each of the donors tested, 
we were able to identify a discrete population of antigen specific T cells using 
HLA peptide tetramers that were responsive to the well known CMVpp65 epitope 
NLVPMVATV (NLV) presented by HLA A0201. Further analysis of these NLV-
specific tetramer positive T cells (NLV-Tet+) demonstrated that the majority of 
memory T cells in peripheral blood that recognize NLV epitope bear either a TCM 
or TEM phenotype (0.9%-31% and 15.1%-70.6% respectively), and the remainder 
were effector T cells. (table. 1) We were also interested to determine if there was 
a population of TSCM cells circulating in the peripheral blood of healthy donors 
that were also antigen specific. Of 11 donors tested, 10 had a distinct population 
of TSCM cells within the CD95+ naïve T-cell precursors (CD45RO-CD62L+), that 
could bind to the A2-NLV tetramer (0.6% - 8.3%) (table. 1).    
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Recently, other groups have also demonstrated the feasibility of generating CMV 
specific T cells from the naïve T cell compartment (41, 42). We therefore 
examined the proportion of NLV-Tet+ cells within the CD95 negative naïve T-cells 
(TN).  However, in only 2 of 11 donors could we detect TN cells within the NLV-
Tet+ population in the peripheral blood. Taken together, our data suggest that a 
minor proportion of NLV-tetramer binding CD8 T cells exist within the 
CD45RO−CD62L+ naïve T cell compartment and consist of both the CD95+ TSCM 
and CD95- TN cells. 
3.3. In vitro expanded epitope specific TSCM cells maintain a less differentiated 
memory phenotype during antigen specific stimulation 
We next wished to evaluate which of the memory T cell populations detected in 
these healthy latently infected seropositive donors served as the reservoir of T 
cell immunity from which antigen-specific T cells were generated upon secondary 
challenge. Based on the properties of TSCM cells described earlier, we particularly 
wished to comparatively assess the potential of CMV-specific TSCM cells to 
expand and act as a durable T cell reservoir.  Accordingly we FACS sorted TN, 
TSCM, TCM and TEM cell populations from HLA-A 0201 CMV-seropositive donors 
as described above using the expression markers CD62L, CD45RO and CD95. 
We then sensitized the sorted T cell subsets with artificial antigen presenting 
cells (AAPCs) exclusively expressing HLA-A 0201, CMVpp65 and T cell 
costimulatory molecules as previously described (30). Cell cultures were also 
supplemented with IL-7 and IL-15 every 2 days beginning at day 4 as previously 
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described (34). 
Using this method for in vitro sensitization of TSCM derived cells, HLA-A 0201 
NLV-tetramer+ CD8+ T cells could be enriched up to 5.5 % by 7 days from 0.6 % 
at day 0 as shown for one representative donor (figure. 3A). A similar enrichment 
of HLA-A 0201 NLV-tetramer+ T cells was also observed within the TCM and TEM 
derived CD8+ T cells (6.1% and 4.1% respectively) (figure. 3A). Over a period of 
4 weeks after antigen specific in vitro sensitization, TSCM derived cells gradually 
acquired TCM and TEM phenotype within both the NLV-Tet+ as well as NLV-
Tet- cell populations (figure. 3B and 3C). Strikingly, within the NLV-Tet+ cells 
derived from the TSCM subset, we were able to detect a proportion of cells with a 
CD45RA+ and CD62L+ TSCM phenotype for up to 14 days in culture. By this time, 
both TCM and TEM derived T cells exclusively expressed a TEM phenotype (figure. 
3B). We also detected higher CCR7 expression within both the NLV-Tet+ as well 
as NLV-Tet- T cells derived from TSCM derived T cells after 14 days of antigen 
specific stimulation in comparison to TCM and TEM derived T-cells. CCR7 was 
expressed in 7.5% of TSCM derived NLV-Tet+ T cells (figure. 3B). These data 
suggest that the TSCM cells follow a differentiation trajectory progressing to TCM, 
and then TEM cells during in vitro expansion. These results also suggest that TSCM 
cells have the ability to maintain a less differentiated phenotype longer than TCM 
derived T cell subsets.   
Using the same approach, we have also been able to generate CMV-specific T 
cells derived from CD95- TN cells. Regardless of whether or not NLV-Tet+ cells 
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were detected in the sorted TN cells within the peripheral blood before antigen 
stimulation, we were able to generate NLV-Tet+ T cells from 6 of 6 different 
donors by this method of sensitization from sorted TN cells. Upon stimulation, TN 
cells upregulated CD95 expression within 2 days and converted to a TSCM 
phenotype. TN cells however, maintained a less differentiated memory 
phenotype, with expression of CD62L and CCR7 within a proportion of NLV-Tet+ 
T cells for a longer duration during antigenic stimulation than the TCM and TEM 
derived cell subsets. In a representative example (figure. 3B), TN derived T cells 
demonstrated CCR7 expression in 12% of NLV-Tet+ T cells, and TSCM derived T 
cells in 7.5% of NLV-Tet+ T cells after 14 days of continuous antigenic 
stimulation, compared to 0.8% and 0.5% CCR7 expressing NLV-Tet+ T-cells 
within TCM and TEM derived T-cells respectively. In the group of 6 donors tested, 
the expression of CCR7 after 14 days of in vitro stimulation in TN and TSCM 
derived NLV-Tet+ T cells was significantly higher than that observed in TCM and 
TEM derived NLV-Tet+ T-cells (p< 0.05) (figure. 3D). A similar trend for CCR7 
expression was also observed in the NLV-Tet negative TN and TSCM derived T 
cells (figure. 3E).  These studies thus demonstrate a less differentiated 
phenotype within antigen experienced T cells derived from TN and TSCM.  
However, the enrichment of NLV-Tet+ populations was less pronounced within 
the TN derived T cells (0.4%, 0.4% and 3.6% at Day 7, 14 and 30 as shown in 
figure. 3A, 3B and 3C) than within T cells derived from the memory T cell 
populations (TSCM, TCM and TEM).  This slow enrichment of CMV-specific T cells 
may reflect the low precursor frequencies in TN subsets in the peripheral blood.         
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3.4. Characterization of the co-stimulatory and senescence markers within 
memory T-cell populations  
We next evaluated characteristics within the naïve and different memory T cell 
subsets, which would identify a particular subset with higher potential for 
proliferation and persistence. Accordingly, we assessed the expression of a 
panel of markers including the co-stimulatory markers CD27 and CD28 as well 
as the IL-7Rα CD127, the activation marker PD-1 and the senescence marker 
CD57. We compared the expression of each of these markers in cells that 
recognize the same antigen to rule out differences occurring as a result of 
differential enrichment of antigen specific T cells within each subset.   
CD27 is constitutively expressed as a costimulatory molecule on all T-cells, but is 
highest on naïve and less differentiated memory T cells. (16) Its expression is 
lost at the fully differentiated effector phase. (43) A recent study also 
demonstrated that CD27 costimulation improves the function of chimeric antigen 
receptor modified T cells (CARs). (44) In our studies, we found a significantly 
higher proportion of cells expressing CD27 within both the NLV-Tet+ and Tet- T-
cells in TN derived cells compared to TCM and TEM derived cells, and TSCM derived 
T-cells compared to TEM derived cells, in 6 donors tested (**p<0.01 and *p<0.05) 
(figure. 4A and 4B). 
CD57 has been described to be indicative of replicative senescence and antigen-
induced apoptosis in HIV-specific CD8+ T cells (45).  After second antigen 
specific stimulation, we found a significantly lower proportion of CD57 expressing 
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cells within TN-derived NLV-Tet+ T cells, compared to TCM and TEM-derived NLV-
Tet+ T cells as shown for 6 donors tested (**p<0.01 and *p<0.05) (figure. 4C and 
4D). TSCM derived cells expressed lower levels of CD57 than TCM and TEM derived 
T cells, though this difference was not statistically significant for the donors 
tested. Again, expression of CD57 was lower on Tet- TN cells, but was similar in 
its expression when compared to Tet+ T-cells in each of the memory T-cell 
subsets (figure. 4C and 4D). These data thus demonstrate increasing levels of 
CD57 expression with increasing T-cell differentiation (TN < TSCM < TCM <TEM) in 
both NLV-Tet+ and Tet- T-cells. 
We next examined the expression of the IL-7Rα (CD127), which has been shown 
to facilitate T cell engraftment and persistence in mouse models (46). In our 
studies, expression of CD127 was lower in both Tet+ and Tet- TN, TCM and TEM.  A 
slightly higher level of CD127 expression was observed within TSCM derived NLV-
Tet+ and Tet- T-cells compared to TN, TCM or TEM derived cells. However, this 
difference was not statistically significant (figure. 4E and 4F). Taken together, 
these data suggest that T cells derived from the TN and TSCM memory subsets 
demonstrate a less differentiated CCR7hi CD27hi and CD57low phenotype when 
compared to TCM and TEM derived T cells whether they are antigen specific (Tet+) 
or not (Tet-).  
We also examined the expression of another protein considered a marker of late 
differentiation, KLRG-1 (47). As shown in figure 4G and 4H, KLRG-1 was 
expressed at low or undetectable levels in Tet- TN cells, but at significantly higher 
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levels in Tet+ TN cells. However, like the other differentiation markers previously 
examined, expression on Tet+ and Tet- T-cells was equivalent in TSCM, TCM and 
TEM. 
In contrast to these differentiate markers, two signaling molecules, PD-1 and 
CD28, were differentially expressed by NLV-Tet+ T cells at each stage of T cell 
development. As shown in figure 4I and 4J, PD-1 is highly and equivalently 
expressed in NLV-Tet+ T-cells at all stages of development, from TN to TEM. In 
contrast, it is expressed at minimal level by NLV-Tet- T-cells. These differences 
are highly significant (Tet+ TN vs Tet- TN ***p < 0.001; Tet+ TSCM vs Tet- TSCM ***p 
< 0.001; Tet+ TCM vs Tet- TCM **p < 0.01; Tet+ TEM vs Tet- TEM **p < 0.01; 
Wilcoxon signed rank test)  
On the other hand, while expression of CD28 was equivalent in Tet+ and Tet- TN 
and TSCM cells, and was also similar in it’s expression in Tet- TCM and TEM cells, 
Tet+ TCM and TEM had a higher level of expression than Tet- TCM and TEM cells 
(figure. 4K and 4L). Expression of CD28 in Tet+ TEM was, in fact, significantly 
higher than that expressed in Tet+ TN derived cells.  
3.5. TSCM derived T cells demonstrate higher proliferative capacity and superior 
expansion of antigen-specific T cells 
We next evaluated the in vitro proliferative capacity of different memory T-cell 
subsets upon antigen specific stimulation with AAPCs expressing CMVpp65, and 
examined the phenotype of proliferating T cells using EdU labeling (see 
methods). Within the total T-cell populations stimulated, we observed vigorous T 
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cell proliferation starting at 3 days after stimulation.  Within the NLV-Tet+ T cells 
10.2% proliferating cells were observed in a representative donor at day 3, 
reaching a peak of 52.2% by day 5 post stimulation (figure. 5A). The less 
differentiated TSCM and TCM cells constituted 32% and 23% respectively, of the 
proliferating memory NLV-Tet+ T cells at day 3 (figure. 5B).  At this time the total 
NLV-Tet+ cells contained 22% of TSCM cells and 32% TCM cells.  By day 5, the 
TSCM and TCM subsets represented 21% of the proliferating memory NLV-Tet+ T-
cells, while they represented 13% of the total NLV-Tet+ memory T cell 
compartment (figure. 5B).  These data suggest that in response to antigen 
stimulation, there is an early preferential proliferation of NLV-Tet+ TSCM and TCM. 
By day 7 post stimulation, 98.6% of the NLV-Tet+ T-cells exhibit a TEM phenotype 
in this donor, and at this time almost all of them proliferating NLV-Tet+ T-cells are 
also TEM. To compare the proliferative potential of each memory subset we 
examined the fold expansion of NLV-Tet+ T cells derived from each of these 
naïve and memory subsets. The yield of antigen-specific T-cells was calculated 
and normalized to the number of NLV-Tet+ T-cells present in peripheral blood. 
After two rounds of antigen exposure, we observed a significantly higher fold 
expansion of antigen-specific T-cells within TSCM derived cells compared to TEM 
derived cells (p=0.03) (figure. 5C).  Although the overall fold expansion of TCM 
derived NLV Tet+ T-cells was lower than TSCM derived cells, this difference was 
not statistically significant. We were not able to perform the same analysis for 
some of the TN donors due to undetectable levels of NLV-Tet+ T-cells in 
peripheral blood before antigen stimulation. Taken together, these data indicate 
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that cells derived from the TSCM demonstrate greater proliferation of antigen 
specific cells and may serve as a significant source of other subsets in the T-cell 
memory pool. 
3.6. In vitro expanded TN and TSCM derived T-cells demonstrate functional activity 
against specific epitopes similar to that of TCM and TEM 
Given that the epitope specific TN and TSCM cells maintain a less differentiated 
phenotype during in vitro expansion, we examined if this would affect their 
antigen-specific functional activity. Accordingly, we evaluated the ability of cells 
derived from naïve and memory T-cell subsets to generate cytokines in response 
to secondary stimulation with antigen.  CD137 has been described as a marker 
of antigen-specific CD8+ T cells that correlates with functional activity including 
production of cytokines such as TNF-α and IFN-γ, as well as granzyme 
production and cytotoxicity activity (48).  Isolated and in vitro expanded naïve 
and memory derived T cells were secondarily stimulated for 15 hours with 
autologous NLV peptide loaded BLCLs. Following antigen stimulation, an 
increased proportion of CD8+ CD137 expressing T cells was observed, as shown 
for a representative donor in figure 6A (TN: 3.36%, TSCM: 37%, TCM, 90.4% and 
TEM 82%). T-cells derived from all subsets, TN, TSCM, TCM and TEM, were able to 
produce cytokines.  Of note, TN and TSCM derived T cells were also capable of 
secreting both TNF-α and IFN-γ, as observed for TCM and TEM derived T cells. 
Complementing their capacity to secrete cytokines, TN and TSCM cells also 
expressed the lysosomal associated membrane protein 1 (LAMP-1) or CD107a 
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which is a marker of degranulation in T cells, in response to peptide loaded 
autologous targets. The level of CD107a in TN and TSCM cells in the CD8+ T cell 
population was 20% and 22% respectively (figure 6B). Thus, although these 
epitope specific TN and TSCM derived T cells, after expansion in vitro, 
demonstrate a less differentiated memory phenotype than TCM or TEM, they are 
functional as evidenced by their ability to secrete cytokines and degranulate in 
response to antigen. 
3.7. TSCM derived CMV-specific T cells differentially exhibit a similar oligoclonal 
repertoire of public TCRs as that of TCM and TEM populations in the blood 
We next examined the clonal diversity of NLV-Tet+ T cells comparing those 
derived from Tet+ TN, TSCM, TCM and TEM. In these studies we wanted to evaluate 
if there were common TCR sequences within CMV-specific T cells derived from 
TN, TSCM, TCM and TEM cells. Accordingly, we expanded TN, TSCM, TCM and TEM 
derived T cells in vitro from 2 donors using our artificial antigen presenting cells 
for 30 days, and sorted the NLV-Tet+ T cells and NLV-Tet- T cells. We then 
performed TCR repertoire analysis by next generation sequencing on the sorted 
Tet+ T cells in comparison to the Tet- T cells. TCR sequencing data were 
analyzed for similarities in nucleotide sequences by sample overlap. This 
analysis of Tet+ T cells from donor CK200D demonstrated a high overlap 
between TCR sequences for TCM and TEM derived NLV-Tet+ cells 30 days post 
stimulation (96% overlap in figure. 7A). TSCM derived cells demonstrated high 
similarities with TN and TCM but less similarity with TEM derived cells (TN: 84%, 
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TCM, 91% and TEM 57% in figure. 7A). In this donor, TN derived Tet+ cells also had 
a high degree of TCR similarity/overlap with Tet+ TCM derived cells (87%) but very 
little overlap with TEM derived cells (14%). In contrast, we did not detect any TCR 
overlap within NLV-Tet- T cells derived from either naïve or memory T cells 
(figure. 7B). Overall, these data indicate that by day 30 Tet+ T cells recognizing 
the NLV epitope that are derived from the naïve like TN subset demonstrate a 
high degree of overlap with TCR sequences expressed by TSCM and TCM. While 
the TCR sequences detected in TSCM and TCM memory T-cells were less 
frequently detected in the TEM, nevertheless, there was a significant 
representation of specific TCRs common to all memory T cell compartments.  
In a second and informative donor CK-42202, we examined if the same trend of 
TCR overlap would be present prior to antigen stimulation in peripheral blood. 
We therefore sorted TN, TSCM, TCM and TEM derived the NLV-Tet+ T cells from the 
donor prior to stimulation and evaluated the TCR sequence for clonality and 
overlap.  TCR clonality describes the degree to which one or a few clones 
dominate the repertoire, with 0 being a flat distribution and 1 being an entirely 
oligoclonal sample. Prior to antigenic stimulation, TEM derived NLV-Tet+ T cells 
demonstrated a high degree of clonality, with a clonality index of 0.66. In 
comparison, the TCM derived NLV Tet+ T cells demonstrated a clonality index of 
0.06 suggesting higher TCR clonal diversity, while the circulating TSCM and TN 
derived NLV Tet+ T cells were highly diverse with a clonal index of 0.01 
(figure.8A). In overlap analysis comparing the Tet+ T cells in the different 
subsets, however, T cells detected in the TEM fraction were also differentially 
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represented in the TCM repertoire. (93.8% in figure 8B) On the other hand, TSCM 
cells, which had a highly diverse TCR repertoire, demonstrate very little overlap 
with TCM and TEM TCR sequences (13.2% and 24.6% respectively; figure 8B). 
Strikingly, we did not identify any TCR overlap between TN derived NLV-Tet+ T 
cells and TSCM, TCM or TEM derived NLV-Tet+ T cells in peripheral blood (figure 
8B).  
After 15 days of antigenic stimulation in vitro, the expanded NLV-Tet+ T cells 
adopted a restricted clonal diversity, with the clonality index ranging from 0.35 to 
0.83 in all subsets (Fig. 8A). In overlap analysis, the TCM and TEM derived NLV-
Tet+ T cells demonstrated highly overlapping TCR sequences in 97.1% of the 
cells (Fig. 8C). Strikingly, TSCM derived NLV-Tet+ T cells developed a restricted 
TCR repertoire within 15 days post antigenic stimulation, which was highly similar 
to that of TCM and TEM derived NLV-Tet+ T cells detected at Day 0 (Fig. 8E) as 
well as Day 15 (TSCM/TCM: 85.8% and TSCM/TEM: 94.8% in figure 8C). Unlike the 
TSCM early after re-stimulation, TN-derived NLV-Tet+ T cells demonstrated very 
different TCR sequences compared to TCM and TEM derived cells with an overlap 
of 37.5% and 3.8% respectively (figure 8D). 
These clonal overlaps are further demonstrated in table. 2 which shows CDR3β 
sequences most frequently detected in the NLV-Tet+ TN, TSCM, TCM, and TEM at 0, 
15 and 30 days after in vitro expansion. As can be seen in this case, the TSCM 
preferentially expanded NLV-Tet+ T cells bearing the CASSPQTGASYGYTP 
sequence that is predominant in the TEM and TCM at day 0. In contrast, the TN 
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cells preferentially expanded NLV-Tet+ cells bearing the CASSYVTGTGNYGYTF 
CDR3 sequences not detected in either the TEM or TCM at any time.  
Taken together, these data provide evidence that, upon antigen stimulation, TSCM 
rather than TN rapidly expand T cell clones expressing NLV-specific TCRs 
detected in immunodominant NLV-specific TCM and TEM populations in the 
circulation.  On the other hand, TN-derived cells can maintain a potential for 
diversity that may not be shared by TSCM which may already be committed to 
sustaining populations of the immunodominant T cells detected in circulating TCM 
and TEM. 
Another feature of the CDR3β sequence, CASSPQTGASYGYTF differentially 
represented in Tet+ NLV-specific TSCM, TCM, and TEM, and the 
CASSYVTGTGNYGYTF CDR3β sequence detected in T cells expanded from TN 
in donor CK42202 is that they are each identical to CDR3β sequences previously 
reported in public NLV-specific T-cell receptors analyzed from other seropositive 
HLA A0201+ donors (49, 50). Similarly, three of the CDR3β sequences highly 
represented in NLV-specific T cells from donor CK200D have the S*nTG*nGY 
CDR3β motif characteristic of these NLV-specific public receptors that are 
prevalent among NLV-specific T cells isolated from HLA A0201+ CMV 
seropositive donors (51).  These public receptors have been reported to be 
usually of high affinity, and can persist as dominant clones for one or more years 
(52). The rapid expansion of T cells bearing such receptors from populations of 
TSCM in which they were initially undetectable raises the possibility that TSCM 
clones may be differentially signaled to respond to alterations in NLV-specific TEM 
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and TCM populations bearing such receptors responding to CMV reactivation. 
3.8. Immunodominance is not caused by the skewed proliferation of TSCM cells in 
circulation 
We have provided evidence that TSCM derived T cells demonstrate higher 
proliferative capacity generating superior expansion of Ag-specific T-cells. We 
next asked whether the phenomenon of epitope specific T-cell 
immunodominance could be a consequence of either over representation of or 
preferential proliferation of TSCM cells within T-cells responding to 
immunodominant compared to subdominant epitopes. To address this question, 
we compared the in vitro T-cell proliferative capacity within TSCM, TCM, and TEM 
subsets upon antigen specific stimulation in a CMV seropositive donor co-
inheriting HLA-A*0201 and A*2402.  The immunodominant anti-CMV T-cell 
response in donors co-inheriting these alleles has been shown to be directed 
against the NLV epitope presented by HLA-A*0201 (lidehall et al.).  T-cells from 
the same donor were stimulated with NLV and QYD loaded autologous DC.  
Within 8 days post stimulation, NLV-Tet+ cells were enriched to 31.7% and QYD-
Tet+ cells to 1.6% representing the immunodominant and subdominant response 
respectively (Fig. 9A). Strikingly, we found a similar memory phenotype for both 
A2-NLV and A24-QYD T-cells, with no overrepresentation of T cells within the 
immunodominant A2-NLV cells in culture.  To further evaluate the relative 
proliferative potential between immunodominant and subdominant epitope 
specific T-cells, we examined T-cells for EdU and Annexin V expression as 
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proliferation and apoptosis markers.  We found similar levels of proliferating cells 
within A2-NLV and A24-QYD Tet+ T-cells, with no preferential proliferation within 
the immunodominant A2-NLV T-cells.  However, the A24-QYD T-cells contained 
a higher percentage of Annexin V+ cells compared to A2-NLV T-cells (figure 9B). 
These data suggest that a higher level of T-cell apoptosis within subdominant 
epitope-specific T-cells might promote the preferential enrichment of 
immunodominant T-cells.   
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4. Discussion 
In this study, we have characterized HLA A0201 restricted TN, TSCM, TCM and TEM 
specific for the immunodominant NLV peptide of CMVpp65 that were isolated by 
immunoadsorption to tetramers from the blood of healthy seropositive donors 
and after sequential intervals of in vitro sensitization. We also compared the 
NLV-Tet+ with Tet- T cells from the same T cell populations. Our results suggest 
a major role for TSCM cells as a durable reservoir of T cell memory in the recall 
immune response.   
Analysis of circulating antigen specific T cells within different memory T cell 
compartments demonstrated that NLV-Tet+ TSCM express a CD45RA+ CCR7+ and 
CD62L+ phenotype similar to TN cells, but unlike TN cells, also express CD95. 
Both NLV-Tet+ and Tet- T-cells derived from TN and TSCM expressed significantly 
higher levels of the costimulatory marker CD27 than NLV-Tet+ and Tet- T cells 
generated from TCM and TEM. Both Tet+ and Tet- TSCM derived T-cells also 
demonstrated somewhat higher expression of the IL-7 Rα (CD127). Restifo et. al. 
have reported high levels of expression of CD127 in TN, TSCM, TCM and TEM in the 
blood of healthy donors (16). However, Schmueck-Henneresse et. al. (39) have 
reported that expression of CD127 is down regulated in TCM and TEM during 
growth in vitro when the cells are cultured with IL-7 and IL-15. In contrast, CD127 
expression, while initially reduced, rapidly recovered in TSCM. To what degree the 
differentiated expression of CD127 observed in NLV-Tet+ TSCM in our own and 
their study contributes to the higher proliferation potential that we observed in 
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NLV-Tet+ TSCM remains to be determined. Conversely, the Tet+ TN and TSCM 
derived cells expressed lower levels of the senescence marker CD57; and Tet+ 
TN expressed lower levels of CD28. Thus, even though the TN and TSCM derived 
T cells, after 14 days of culture, had largely progressed to a TCM or TEM 
phenotype, they still expressed markers found on less differentiated T cells and 
low levels of markers associated with terminal differentiation or senescence.  
Strikingly, after in vitro sensitization, all Tet+ subsets generated a similarly high 
proportion of cells expressing PD-1, which differed significantly from the low 
proportion of PD-1+ cells in the Tet- population.  PD1 has been thought to be a 
marker of T cell exhaustion in animal models of chronic infection and within TILs 
reactive to specific self tumor antigens.  However, this protein has been found to 
be upregulated upon antigen engagement and therefore has also been thought 
to represent activated antigen specific T-cells (53).  In addition, the killer-cell 
lectin like receptor G1 (KLRG1), which is usually considered to be a marker of 
late differentiation was expressed to a similar degree in the NLV-Tet+ and Tet- 
TSCM, TCM and TEM fractions (47). In contrast, KLRG-1 was expressed at a 
minimal level in the Tet- TN derived cells but at levels similar to those in TSCM, TCM 
and TEM after antigen stimulation. Thus, in latently infected healthy seropositive 
individuals, secondary stimulation with the viral antigen induces expression of 
PD-1 in TN and in all stages of T-cell memory and KLRG-1 in antigen responsive 
TN-derived cells. 
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At a functional level, Tet+ TN, TSCM, TCM and TEM fraction all contained cells 
capable of secreting TNF- and IFN-, and degranulating in response to antigen 
stimulation, although the proportion of Tet+ T cells derived from TEM and TCM 
exhibiting these functions were higher than in Tet+ T cells derived from TSCM or 
TN. Thus, in contrast to a previous report in which only a minimal number of 
CD95- T cells were found to secrete cytokines after HCMV-specific stimulation 
(39), our studies provide evidence that TN cells, after antigen stimulation, do 
exhibit these effector functions and cannot, thereby, be qualitatively distinguished 
from antigen-responsive TSCM cells. Recent studies by Pulko et al (54) have also 
shown that human memory T cells with a naïve phenotype secrete multiple 
cytokines in response to secondary stimulation with viral antigens but exhibit 
longer telomeres and a distinct transcriptome that differentiates them from 
memory and effector T cells. We also find that NLV-Tet+ CD95- TN cells are 
functionally distinguishable from NLV-Tet+ CD95+ TSCM cells in that they exhibit a 
markedly lower proliferative response to antigen stimulation. Indeed, the 
proliferative response of TSCM significantly exceeds not only that of NLV-Tet+ T 
cells derived from the TN fraction but also NLV-Tet+ T cells derived from TCM and 
TEM.  
A diverse TCR repertoire has been postulated to mediate optimal control of 
pathogens by increasing the probability that microbial escape mutations would be 
recognized by one of the TCR pairs represented within the repertoire (55, 56). 
Our TCR sequencing analysis has shown that in the peripheral circulation, the TN 
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and TSCM cells recognizing the same epitope NLV, are more diverse than TCM 
and TEM cells. This broad TCR repertoire of TN and TSCM cells recognizing the 
same pathogen could be hypothesized to provide better control of virus infection. 
However, upon antigen stimulation, we observe that TSCM generate T cells that 
are oligoclonal within 15 days after antigen encounter, and further that these T 
cells express a repertoire closely related to that of Tet+ TEM and TCM that are 
dominant in the circulation. The fact that TSCM derived CMV-specific cells share 
high overlap of TCR usage with TCM and TEM early post stimulation, provides 
evidence that TSCM derived cells are particularly effective in reconstituting 
populations of immunodominant memory T cells in the blood. The fact that the 
oligoclonal NLV-specific Tet+ TCM and TEM in the blood, and the responding TSCM 
of donor CK 42202 differentially express a TCR with the same public CDR3β, 
and that the most prevalent NLV-Tet+ TCM and TEM from both donors express T 
cell receptors bearing such public CDR3βs is also consistent with previous 
studies indicating the importance of such public T-cell receptors to the control of 
latent infections and to effective responses to CMV reactivation (57, 58).  In CMV 
seropositive healthy donors, NLV peptide specific T cell repertoires exhibit a high 
prevalence of public TCRs. (51, 52, 59).  Indeed, seven public CDR3α and six 
CDR3β motifs have been estimated to account for up to 70% of the total NLV- 
specific TCR response (51). Studies of the crystal structures of the two public 
TCRs in complex with NLV-HLA A2 have provided evidence that different 
pairings of TCRα and β chains bearing public CDR3 sequences can engender a 
multiplicity of high affinity TCRs engaging the same peptide-MHC ligand (58), 
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thereby also providing a diversity of effective T cells specific for the 
immunodominant NLV epitope. In contrast, the more heterogeneous and 
distinctive spectrum of clones generated from TN cells after antigen stimulation, 
which differs from that of the other memory T- cell compartments, suggests that 
TN cells serve as a pool of precursor cells capable of selecting peptide-specific T 
cells with a broader spectrum of binding characteristics, from which antigen-
specific T cells of optimal avidity can be selected for expansion if required to 
control viral variants. 
T cell responses to latent viruses are often focused on a small number of the 
available antigenic epitopes and use a narrow TCR repertoire, a phenomenon 
termed “immunodominance”. A number of factors have been reported to 
influence immunodominance, including antigen presentation, peptide-MHC 
binding affinity and stability or TCR avidity and the frequency of precursors in the 
naïve T-cell pool (60). In the two donors we tested, we did not find an over-
representation or preferential proliferation of TSCM cells within T-cells responding 
to immunodominant compared to subdominant epitopes. Instead, we detected a 
higher level of T-cell apoptosis within subdominant epitope-specific T-cells, which 
might promote the preferential enrichment of immunodominant T-cells.  Previous 
studies have also indicated that the characteristics of TCR binding to pMHC 
complexes may also regulate clonal apoptosis (61). Indeed, TCRs with a 
subthreshold affinity for pMHCI preferentially undergo apoptosis early in the 
response via a process that is regulated by the BCL-2 family members BIM, 
NOXA and MCL1 (62). Thus, our data are in accord with that of others and 
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suggest that apoptosis may also be crucial for shaping adaptive immune 
responses, thereby enhancing the selection of clones with greater persistence. 
In conclusion, our studies demonstrated that both antigen-specific Tet+ T cells 
and Tet- T-cells derived from isolated TSCM exhibit and maintain a less 
differentiated phenotype than other memory T cell populations. Second, while we 
could regularly expand Tet+ NLV-specific T cells from the CD95- TN compartment, 
antigen-specific T cells expanded from TSCM cells differ from Tet+ TN as well as 
TCM and TEM derived T cells in that they proliferate to a much higher degree in 
response to antigen stimulation. Third, we find that antigen-sensitized Tet+ TN 
and Tet+ TSCM, unlike Tet- TN and TSCM, express PD-1 at levels similar to those 
expressed by Tet+ TCM and TEM. They also exhibit effector function, indicated by 
the capacity to generate TNF-, IFN- and expression of the degranulation 
marker CD107a. Fourth, we demonstrate that, in response to antigen stimulation, 
TSCM not only undergo marked proliferation but also rapidly select T cell clones 
specific for the CMVpp65 NLV epitope presented by HLA-A 0201 that, by TCR 
sequencing, are public TCRs identical to those expressed by Tet+ NLV-specific 
TEM and TCM that are immunodominant in the blood. In contrast, the NLV-Tet+ TN 
cells can generate a distinct and more varied repertoire than that detected in 
NLV-specific TCM and TEM in the blood, or in TSCM after 15 days of in vitro 
stimulation. Taken together, these findings provide evidence that TSCM constitute 
the principal reservoir for rapid repopulation of immunodominant of NLV-specific 
TCM and TEM that are maintained in the circulation.  
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Our findings have implications for the design of T cell-based immunotherapies, in 
that, adoptive transfer of virus-specific T cell lines enriched for TSCM could 
potentially provide better disease control by facilitating early recovery of those 
immunodominant virus-specific T cells that normally control latent infection and 
provide sustained long term protection from disease. 
 
  
98
  
 
 
 
 
 
Figure 1.   
Comparison with different cytokine treatments for generating antigen-specific 
human T cells in vitro 
T cells sensitized with AAPC transduced to express CMV pp65 with different cytokine 
treatments. Antigen-specific T cells was evaluated by HLA-A2-NLV tetramer binding 
gated on CD8 T cells. (A) Numbers of antigen-specific T cells were calculated from the 
percentage of antigen-specific T cells in culture.  (B) Fold expansion of antigen-specific 
T cells were normalized from T cells before antigen sensitization at day0. 
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Figure 2.  
 Isolation and characterization of TN, TSCM, TCM and TEM populations from human 
peripheral blood 
Flow cytometry was used to isolate the TN, TSCM, TCM and TEM subsets from PBMC.  
Lymphocytes were first gated within PBMC by forward and side scatter and analyzed for 
CD45RO, CD95, CD62L and CD3 expression. CD3+ lymphocytes were then gated for 
CD45RO+CD62L+ TCM and CD45RO+CD62L- TEM, CD45RO-CD62L+CD95+ TSCM cells 
and CD45RO-CD62L+CD95- TN cells. 
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Table 1. 
Composition of naïve and memory TN, TSCM, TCM and TEM) CD8 T cells in 
healthy CMV seropositive individuals 
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Donor TEM TCM TSCM  TN Tet+ TEM TCM TSCM  TN
1 31.9 8.7 4.2 8.7 2.5 35.4 1.1 0.6 ND
2 31.7 7.0 2.5 28.9 4.4 15.1 0.9 2.0 0.2
3 27.4 20.3 5.8 16.0 0.9 47.9 8.3 3.7 ND
4 22.2 13.8 3.8 22.0 0.4 59.7 9.7 2.4 ND
5 34.9 11.0 2.1 5.0 0.5 42.0 1.4 1.4 ND
6 33.0 12.8 3.1 6.0 0.3 79.7 3.4 1.7 ND
7 18.1 32.4 1.2 17.3 2.0 60.2 31.0 6.3 ND
8 21.0 13.0 1.9 28.6 0.1 41.7 2.1 8.3 ND
9 28.4 8.3 10.8 23.5 1.5 70.6 5.9 ND ND
10 15.4 3.6 2.6 21.8 NA
11 25.6 1.7 2.0 6.5 1.0 27.8 3.5 3.0 0.1
12 28.9 3.5 2.4 3.8 0.3 35.8 5.3 2.0 ND
Within T cell population Within NLV‐Tet+ population
(ND=	not	detectable;	NA=	not	applicable) 
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Figure 3.  
 Phenotypic characterization of naïve and memory (TN, TSCM, TCM and TEM) derived 
CMV-specific CD8 T cells upon antigen stimulation 
Isolated T cells from TN, TSCM, TCM and TEM cell populations were sensitized with artificial 
antigen presenting cells (AAPCs) expressing CMVpp65 peptide and HLA-A 0201.  T 
cells were evaluated at 7, 14 and 30 days post stimulation. As shown for a 
representative donor in panel (A), (B) and (C) CD8+ single, live T cells were gated from 
CD3+ T lymphocytes.  HLA –A 0201-NLV Tet+ and NLV-Tet- T-cells were then gated 
within CD8+ T-cells (left panel), and expression frequencies of CD62L, CCR7 and 
CD45RA gated on NLV-Tet+ and NLV-Tet- population is shown in the middle and right 
panel (Red: NLV-Tet+; Blue: NLV-Tet-).   The proportion of CCR7 expressing T-cells 
post antigenic stimulation are shown for 6 donors tested within (D) NLV-Tet+ and (E) 
NLV-Tet-. (*P < 0.05; **P < 0.01 by Mann-Whitney test) 
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Figure	3	(Continued)	
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Figure	3	(Continued)	
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Figure	3	(Continued)	
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Figure 4. 
Distinct expression of co-stimulatory and senescence markers within TN, TSCM, 
TCM and TEM 
Expression frequencies of CD27, CD57 CD127, CD28, KLRG1, PD1 and CD28 gated 
on NLV-Tet+ and NLV-Tet- population after 14 – 18 days of in-vitro stimulation are 
shown for T-cells expanded from each T-cell subset TN, TSCM, TCM and TEM. CD27 
expression within (A) NLV-Tet+ and (B) NLV-Tet - CD8+ T cells is shown for 6 donors 
tested. CD57 expressing (C) NLV-Tet+ and (D) NLV-Tet- CD8+ T-cells is shown for 8 
donors tested.  CD 127 expression within (E) NLV-Tet+ and (F) NLV-Tet- CD8+ T-cells is 
also shown for 6 donors tested. Within NLV-Tet+ and NLV-Tet- CD8+ T-cells, the 
expression levels of KLRG1 (G) and (H), PD-1 (I) and (J)  and CD28 (K) and (L) are 
shown for 9, 11 and 6 donors tested respectively.  (*P < 0.05; **P < 0.01 by Mann-
Whitney test) 
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Figure	4	(Continued)	
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Figure 5. 
  Enrichment of CMV-specific CD8 T cells results from rapid expansion of early 
memory T cells 
(A) In-vitro proliferation of A2-NLV-Tet + T cells was evaluated after in-vitro sensitization 
with CMVpp65 antigen by EdU as shown in a representative donor on Day 3, 5 and 7 
post- stimulation. CD3+ T cells were sensitized with artificial antigen presenting cells 
(AAPCs) expressing CMVpp65 peptide and HLA-A 0201. The enrichment of NLV-Tet+ 
cell after stimulation was evaluated as shown on the left panel. Percentage of EdU 
expression gated on single, live CD8+ T lymphocytes is shown in the middle panel. 
Percentage of EdU expression gated on NLV-Tet+ CD8+ T-cells is shown on the right 
panel. (B) Phenotypic analysis of NLV-Tet+ cells (left panel) in comparison to NLV-Tet+ 
cells with EdU incorporation is shown for a representative donor on the right panel. 
(Blue: CD45RO+CD62L- TEM; Red: CD45RO+CD62L+ TCM; Green: CD45RO-
CD62L+CD95+ TSCM) CD45RO-CD62L+CD95- TN cells were not detected post antigen 
stimulation. Fold expansion of A2-NLV-Tet (+) T cells (B) before antigen specific T-cell 
stimulation and (C) after 14 days of antigen specific T-cell stimulation was evaluated 
within NLV-Tet+ CD8 T cells within the TN, TSCM, TCM and TEM subsets. NLV-Tet+ CD8 T 
cells in TN population was not detected in 4 out of 6 donor tested before exposure to 
antigen. (n=6) (*P = 0.03; ns, not significant; from Mann-Whitney test). 
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Figure	5	(Continued)	
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Figure 6. 
Functional cytokine profile and cytotoxic activity of in-vitro expanded CMV-
specific T cells derived from naïve (TN) and memory T cells (TSCM, TCM and TEM) 
(A) Expanded naïve and memory T cell populations were stimulated for 18 hours with 
NLV peptide loaded autologous BLCLs at a ratio of 5:1. T-cells co-cultures with 
autologous BLCLs without peptide loading served as controls.  CD8 + T-cells secreting 
IFN-γ and TNF-α were evaluated by intracellular staining within CD137+ T-cells. The 
percentages of CD8+ T cells co-expressing CD137 are shown on the left 2 panels with 
or without peptide stimulation. The proportions of CD137+ CD8+ T-cells secreting IFN-γ 
or TNF-α cytokine are shown in the middle 2 panels. CD137+ CD8+ T cells secreting 
both IFN-γ and TNF-α cytokine are shown in the right panel. (B) Cytotoxic activity was 
evaluated by CD107a degranulation. The percentages of CD8+ T cells demonstrating 
CD107a+ populations with (middle panel) or without (left panel) peptide stimulation are 
shown. CD8+ T cells expressing both CD137 and CD107a are shown in the right panel. 
Data are representative of three experiments (n=3). 
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Figure 7.  
Clonal diversity and clonotype selection after in vitro expansion in CMV-specific 
TN, TSCM, TCM and TEM cells 
Next generation sequencing was performed for TCRVβ repertoire analysis. Heat map 
indicates similarity of sample profiles. The similarity accounts for overlap between 
unique nucleotide sequences within any two samples. (A) and (B) Naïve (TN), and 
memory (TSCM, TCM and TEM) T cell subsets from the same donor after 30 days of in vitro 
expansion were compared for their TCR sequences within (A) NLV-Tet+ and (B) NLV-
Tet- T-cells. 
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Figure 8. 
Tracking of TCR clonotype selection during in vitro expansion 
Sorted NLV-Tet+ T-cells within each TN, TSCM, TCM and TEM subset were subjected to 
next generation sequencing to evaluate TCRVβ repertoire at day 0 before in vitro 
stimulation, 15 days, and 30 days after in vitro stimulation.  (A) TCR clonality was 
analyzed using immunoSEQ Analyzer 2.0 for NLV-Tet+ T cells as well as NLV-Tet- T-
cells contained within sorted TN, TSCM, TCM and TEM T-cell subset populations. The 
degree of clonal dominance (measured by clonality index) within Tet+ T-cells derived 
from TN, TSCM, TCM and TEM T-cell subsets is shown.   The heat maps indicate overlap 
between unique nucleotide sequences within any two samples.  This is shown for each 
time point separately for T cell samples at day 0 (B), 15 days (C) and 30 days (D) after 
in vitro stimulation.  A composite overlap analysis at all time points is shown in (E) for 
the same donor. 
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TSCM 
TCM 
TEM 
30 30 30 30
30
0.443 0.399 0.040
30
0.443 0.876 0.675
30
0.399 0.876 0.945
30
0.040 0.675 0.945
(D) 
Donor	CK-42202 
NLV-Tet+ NLV-Tet+ 
(A) 
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Figure	8	(Continued)	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	 	
TN TSCM TCM TEM 
TN 
TSCM 
TCM 
TEM 
0 15 30 0 15 30 0 15 30 0 15 30
0
0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
15
0.000 0.955 0.003 0.656 0.289 0.008 0.375 0.257 0.207 0.038 0.009
30
0.000 0.955 0.004 0.759 0.443 0.013 0.451 0.399 0.223 0.063 0.040
0
0.000 0.003 0.004 0.862 0.748 0.132 0.535 0.724 0.246 0.152 0.026
15
0.000 0.656 0.759 0.862 0.990 0.876 0.858 0.957 0.897 0.948 0.892
30
0.000 0.289 0.443 0.748 0.990 0.748 0.733 0.876 0.702 0.815 0.675
0
0.000 0.008 0.013 0.132 0.876 0.748 0.661 0.753 0.938 0.403 0.110
15
0.000 0.375 0.451 0.535 0.858 0.733 0.661 0.968 0.965 0.971 0.969
30
0.000 0.257 0.399 0.724 0.957 0.876 0.753 0.968 0.797 0.940 0.945
0
0.000 0.207 0.223 0.246 0.897 0.702 0.938 0.965 0.797 0.961 0.955
15
0.000 0.038 0.063 0.152 0.948 0.815 0.403 0.971 0.940 0.961 0.934
30
0.000 0.009 0.040 0.026 0.892 0.675 0.110 0.969 0.945 0.955 0.934
(E) Donor	CK‐42202 
NLV‐Tet+ 
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Table 2. 
Predominant clonotypes represented within naïve and memory A2-NLV specific 
CD8 T cells in CMV seropositive donors 
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0 15 30 0 15 30 0 15 30 0 15 30
CASSPQTGASYGYTF TCRBV06‐05 TCRBJ01‐02 21.29 10.53 8.13 8.06 46.30 62.72 2.56 83.57 67.66 0.00 0.22 0.11
CASSYVTGTGNYGYTF TCRBV06‐05 TCRBJ01‐02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 88.93 87.14
CSVAGTVNEQFF TCRBV29‐01 TCRBJ02‐01 0.81 22.99 18.87 0.00 5.79 2.94 0.00 9.72 14.59 0.00 0.00 0.00
CAAGGIFGTDTQYF TCRBV27‐01 TCRBJ02‐03 0.00 4.29 5.79 0.00 6.57 5.38 0.00 0.00 0.00 0.00 0.00 0.00
CAWSISDIMNTEAFF TCRBV30‐01 TCRBJ01‐01 0.00 1.80 0.83 0.00 12.31 6.95 0.00 0.00 0.00 0.00 0.00 0.00
CASSLEGYTEAFF TCRBV27‐01 TCRBJ01‐01 6.20 4.99 3.31 2.42 2.99 1.47 0.00 0.00 0.00 0.00 0.00 0.00
CAWSVSDPLNTEAFF TCRBV30‐01 TCRBJ01‐01 1.66 1.52 2.20 2.42 1.18 0.29 0.00 0.00 0.00 0.00 0.00 0.00
CASSPKTGAVYGYTF TCRBV06‐05 TCRBJ01‐02 10.79 73.07 79.73 46.41
CASSHQTSGNTIYF TCRBV19‐01 TCRBJ01‐03 17.04 0.09 0.00 0.00
CASSLKTGASYGYTF TCRBV06‐05 TCRBJ01‐02 1.17 4.64 0.02 1.10
CASSVLAPTVGSTEAFF TCRBV10‐02 TCRBJ01‐01 4.37 3.03 0.00 0.00
CASSYQTGASYGYTF TCRBV06‐05 TCRBJ01‐02 4.22 1.81 0.00 0.00
CASSEIGATNYGYTF TCRBV06‐01 TCRBJ01‐02 2.94 0.16 0.00 0.00
CK‐42202 
NLV pos
CK‐200D 
NLV pos
Freq in different days (%)
TCRBJTCRBVaminoAcidSource
TEM TCM TSCM TN
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Figure 9.   
Immunodominance is not caused by the skewed proliferation of TSCM cells in 
circulation 
(A) T cell population selected from CMV seropositive donor coinheriting HLA A0201 and 
HLA A2402. CD3 T cells sensitized separately with either AAPC coexpressing HLA 
A0201 and CMVpp65 or HLA A2402 and CMV pp65. Flow cytometry was performed to 
evaluate the expression of CD62L and CD45RA within gated Tet+ population after 4, 5, 
7 and 8 days post stimulation (A2: NLV and A24: QYD). The percentages of TSCM, TCM 
and TEM cells were evaluated within Tet+ population (TSCM: CD62L+CD45RA+, TCM: 
CD62L+CD45RA- and TEM: CD62L-CD45RA-) (B) T cell proliferation and apoptosis 
within Tet+ population was evaluated by coexpressing EdU or AnnexinV in comparison 
to A2 NLV-Tet+ and A24 QYD-Tet+ population. 
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Figure	9	(Continued)	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	 	
(B) 
Day	4 
Day	5 
Day	7 
Day	8 
EdU+	NLV-Tet+ EdU+ QYD-Tet+ 
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CHAPTER THREE 
Affinity maturation of TCR-like antibodies for WT1 peptide greatly 
enhances therapeutic potential. 
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1. Introduction 
Virus specific T- cells responding to immunodominant epitopes demonstrate the 
highest functional activity executing effective control of infection. In previous 
studies, we evaluated the in vitro- expansion and functional activity of T-cells 
responding to immunodominant and subdominant epitopes.  These studies did 
not reveal a clear role of TSCM cells in establishing epitope-specific 
immunodominant T-cell populations. The mechanisms of antigen presentation, 
that affect the repertoire of epitope specific T-cells, including peptide MHC-
binding affinity, are very dynamic and primarily focused on the APC.  We sought 
to evaluate the role of T cell receptor affinity on the in vitro expansion and 
functional activity of epitope specific T-cells.  
Antigens expressed on cancer cells are self-antigens.  The human immune 
system has evolved to avoid the generation of high-affinity T cell receptors 
(TCRs) against self-proteins to preclude autoimmune reactions.  In clinical trials, 
T cells directed against tumor antigens have typically demonstrated weak 
responses in vivo. Such tumor antigen specific T-cells have also been shown to 
express TCRs that demonstrate low binding affinity to the target tumor cells. 
Although soluble TCRs have been successfully developed to target T cell epitope 
on tumors, their inherent low affinity has limited their potential as therapeutics 
(63). It was therefore thought that increasing the TCR affinity of the endogenous 
TCRs for tumor antigen specific T-cells would enhance the activity of adoptively 
transferred T-cells directed against cancer antigens. Attempts to affinity mature 
131
	
	
TCRs have been hampered by cross-reactivity (64, 65). Affinity enhanced TCR 
directed to human HLA A01-restricted MAGE A3 antigen, called a3a was 
identified as the most potent MAGEA3-specific TCR. However, when the a3a-
engineered T cells were used in two patients with melanoma, both died through 
off-target toxicity (66). These studies suggest that T cells expressing affinity-
enhanced TCRs directed to the tumor antigen have potent tumor activity, as long 
as improvements in affinity are contained within an appropriate window; above 
this threshold level, efficacy and specificity would be compromised.  In these 
studies, we utilized a chimeric antigen receptor (CAR) based system expressing 
a TCR mimic single chain variable fragment (scFv) directed against the RMF 
epitope of the intracellular protein WT-1 in complex with / presented by HLA 
A0201. We specifically evaluated the in vitro functional activity of CAR modified 
T-cells, that expressed antibodies of both high and low binding affinities to 
determine the differential functional activity between T-cells expressing high and 
low affinity antibodies as a surrogate for high and low affinity TCRs. 
A chimeric antigen receptor (CAR) is a fusion receptor that combines the antigen 
recognition property of an immunoglobulin with a T cell activation domain. A T 
cell engineered to express a CAR has the ability to recognize and bind to cell 
surface antigens via the antibody domain, and then get triggered to be activated 
through the T-cell signaling and co-stimulatory domains (e.g. CD3 zeta, and 4-
1BB), thus emulating interaction with antigen expressing APC. Most CARs 
typically use an antibody-derived antigen-binding motif to recognize native cell-
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surface antigens independently of antigen-processing or major histocompatibility 
complex (MHC) -restricted presentation. Another strategy for retargeting T cells 
to specific antigen expressed on cells consists of TCR-mimic CARs expressing a 
scFv antibody directed against a specific peptide-MHC complex. TCR-like 
antibodies, with high affinity and controlled specificity, could be ideal therapeutics 
(67). To this end, several TCR-like antibodies targeting peptides derived from 
viral or tumor antigens in the context of human leukocyte antigen (HLA)-A1 or 
HLA-A2 have been reported (68-71).  
The Wilms tumor gene 1 is one of the most studied tumor associated 
antigens, which encodes a zinc-finger transcription factor (Wilms tumor protein 1; 
WT1) important in cell growth and differentiation (72). WT1 is over expressed in 
several malignancies such as leukemias, lymphomas and solid tumors including 
astrocytic tumors, sarcomas, breast, lung and colorectal cancer, and 
neuroblastoma (73), with the characteristics of an oncogene (74). Several 
peptides derived from endogenous WT1 protein are presented in the context of 
MHC class I molecules and are immunogenic (75). The 9-mer WT1-derived 
peptide 126–134, RMFPNAPYL (WT1126), is the most extensively studied (76). 
As a vaccine, the WT1126 peptide has induced durable WT1-specific cytotoxic T 
cell (CTL) responses in patients with acute myeloid leukemia (AML) (77).  
We developed a novel TCR-like CAR containing the antibody against 
WT1126/HLA-A2.  T-cells transduced to express these novel CARs that contain 
either a low affinity or a high affinity antibody were used as a surrogate system to 
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evaluate the effect of the binding affinity of the TCR mimic-CAR on the functional 
activity of such CAR expressing T-cells.    
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2. Materials and Methods 
Human lymphocytes and tumor cell lines 
Human peripheral blood mononuclear cells (PBMC) were isolated from whole 
blood by ficoll Hypaque density gradient separation. T cells were purified by 
negative magnetic separation using magnetic beads containing antibodies 
against CD19, CD20, CD14, CD56 (Pan T-cell isolation kit, Miltenyi Biotech). 
Cells were cultured in RPMI 1640 with 2 mM L-glutamine and 10% fetal bovine 
serum (FBS).  
Retroviral production and transduction 
For T-cell or K562 transduction, vector DNA was transfected into H29 packaging 
cells in the presence of CaCl2. Viral supernatant was collected for two 
consecutive days to be stored, or to transfect the PG-13 packaging cell line. PG-
13 cells expressing the transduced vector DNA were sorted using GFP as the 
selection marker, cloned and expanded, and culture supernatants collected for T-
cell transduction. Purified T-cells were first stimulated with CD3/CD28 beads for 
24 hours. PG-13 viral supernatant was added to retronectin coated plates, 
followed by the suspension of T-cells or K562 cells. The plates were spun down 
and incubated for 48 h. Cells expressing the transduced vector were detected 
using GFP and a WT1126/HLA-A2-PE-labeled tetramer by FACS. 
Cytotoxicity Assay 
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The cytolytic capacity of T-cells was tested against HLA-A2/WT1+ tumor cell lines 
as well as autologous EBV-BLCL loaded with the WT1126 peptide using the 
standard 51Cr release assay.  
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3. Results 
3.1 Low affinity T-cell receptor-like CAR T cells were not functional 
Human scFv-specific HLA-A2/WT1126 Clone 45 was isolated and characterized 
by Dr. Nai-Kong V. Cheung’s lab using phage display selection (78). WT1 Clone 
45 scFv was highly specific for the recombinant HLA-A2-RMFPNAPYL complex. 
However, The binding affinity of scFv Clone 45 (KD= 300 nM) was low. We first 
modified CD3 T cells isolated from the peripheral blood of healthy donors, using 
retroviral transduction in vitro with the Clone 45-	 chimeric antigen receptor (CAR) 
from Dr. Cheung’s lab. Transduction efficiency varied between 20% and 40% in 
both CD4 and CD8 T cells. We FACS sorted for GFP+ CD3 T cells expressing 
the Clone 45-CAR in both CD4 and CD8 T cells. We failed to find any HLA-A2-
RMF tetramer positive cells in either CD4 or CD8 GFP+ T cells (figure 1). We 
then evaluated cytotoxicity activity of T cells expressing Clone 45-CAR by 51Cr 
release assay. Cytotoxic activity of Clone 45 CAR+ T cells was examined at an 
E/T ratio of 25:1 and 10:1 using 3 different target tumor cell lines overexpressing 
WT1; OVCAR3/pp65 and HTB37/pp65, which coexpress HLA A0201 and 
SKOV3 which only expresses WT-1. The WT-1 expression level for each of 
these tumor cell lines was evaluated by western blot, and is shown in figure 2A. 
We detected minimal lysis of tumor cells expressing NCA A0201 and C high 
(OVCAR3/pp65) or medium (HTB37/pp65). No lysis was detected against the 
HLA A0201 negative WT-1 low expressing SKOV-3 (figure 2B) with Clone 45 
CAR+ T-cells. We therefore observed that Clone45-CAR expressing T cells not 
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only did not bind to the HLA-A2-RMF tetramer, but also failed to kill the WT1 
expressing tumor targets.  
3.2 Affinity-matured TCR-like CAR T cells greatly enhanced their therapeutic 
potential 
The affinity maturation of Clone 45 was carried out using yeast display by Dr. 
Nai-Kong V. Cheung’s lab (78). Q2L, the affinity-matured clone achieved a 100-
fold improvement in affinity (KD = 3 nM). Compared to reported TCR-like 
antibodies (9.9 to 294 nM) (68), it was the highest among all. We first transduced 
K5G2 cells to express Q2L-CAR so as to validate whether the HLA-A2-RMF 
tetramer can bind to Q2L-CAR. We achieved a 42% transduction efficiency as 
assessed by the percentage of GFP+ cells, and 40% K562 cells demonstrated 
binding to the HLA A0201-RMF Tetramer representing cells expressing the Q2L-
CAR (figure. 3). In GFP expressing cells, almost all of the cells also bound the 
HLA-A2-RMF tetramer, demonstrating that the high affinity Q2L-CAR expressed 
in K562 cells was able to bind to RMF complexed with HLAA0201 (figure. 3A). 
We next isolated CD3+ T cells from the peripheral blood of healthy donors and 
transduced them in vitro to express the Q2L-CAR. HLA-A2-RMF tetramer binding 
was again demonstrated by the transduced CD4 and CD8 T cells that coexpress 
GFP (figure. 3B). In assays testing their specific cytotoxicity against WT1-
expressing tumor targets, we found that T cells transduced to express Q2L-CAR 
mediated efficient tumor cell target lysis. Q2L-CAR modified T cells specifically 
recognized and killed HLA-A2(+)/WT1(+)targets (e.g. BV173, HTB37/pp65 and 
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OVCAR3/pp65 in a dose-dependent manner, but not HLA-A2(-)/WT1(low) cells 
(SKOV3), A2(+)/WT1(−) cells (autologous BLCLs) or A2(-)/WT1(+) cells (K562 
cells) (figure. 3C). Conventional CARs target cell surface protein and are not 
restricted by a particular HLA. Our data indicate that CARs can be genetically 
engineered that are specific for epitopes of processed intracellular proteins that 
are presented by a defined HLA allele, and that T-cells modified to express such 
TCR-like CARs, can exert cytotoxic activity against appropriate target cells 
expressing the CAR targeted HLA-peptide complex.  
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4. Discussion 
In the targeting of class-I peptide-MHC, normal wild-type TCRs with binding 
affinities in the range of 10–300 μM provide sufficiently sensitive responses. In 
studies evaluating various TCRs against MHC class-I - peptide, 300 μM appears 
to be the minimal affinity required for effective CD8 T cell activity, whereas the 
optimal affinity is about 10 μM (79). In our study, we demonstrated that the 
affinity matured Q2L-CAR modified T cells recognized tumor cells in an HLA 
restricted WT1-specific fashion. In contrast, minimal target cell lysis was 
observed using T-cells expressing the low affinity parental Clone 45. Oren et al. 
(71) compared CAR modified T-cells containing either low affinity F2 (400nM Kd) 
or the moderate affinity F3 (30nM kD) scFvs and found that the higher affinity F3-
CAR modified T-cell demonstrated non-specific cross-reactivity, and poor 
viability. They proposed that this off-target activity and poor viability of the F3-
CAR modified T-cells indicates an affinity barrier to developing effective anti-
peptide/HLA CAR T cells.  Here we show that the affinity matrured Q2L CAR can 
retain both target specificity and viability despite having high affinity (3nM KD for 
the scFv). Overall, both our own and other studies clearly demonstrate higher 
cytolytic activity with increasing TCR /CAR binding affinity.  In order to overcome 
the undesirable off-target activity, the isolation of appropriate antibody clones and 
refining the affinity maturation techniques would be critical for further 
development of these approaches.  
Various strategies to improve the affinity of TCRs for adoptive T cell therapy have 
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been explored. While anti-tumor responses have been observed, there have 
been serious adverse events with MART-1 TCRs due to on-target/off-tumor 
activity (80), and lethal events with MAGE-3 TCRs due apparently to off-target 
cross-reactivity with structurally similar epitopes. While there will always remain a 
risk of unpredicted reactivities in patients receiving adoptive T cell therapies, we 
believe that the use of TCRs with different affinities and specificities in an 
expanded set of pre-clinical approaches, will identify some of the possible 
problems (81).  
In summary, we describe an experimental comparison of low versus high affinity 
TCR-like chimeric antigen receptors to evaluate the effect of the binding affinity 
of the TCR mimic-CAR on the functional activity. Our studies validate the 
superior specific binding and HLA-restricted WT-1 peptide specific cytoxicity of T-
cell expressing the high affinity CAR against HLA A0201+WT-1+ human tumor 
cells.  This study highlights the importance of TCR affinity to the T-cell’s 
functional activity.  In conclusion, in order to develop a strategy for antigen-
specific T-cells to provide long lasting immunity against antigens, the affinity 
barrier of TCR has to be reached to develop effective function for adoptive T cell 
transfer. 
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Figure 1. 
Human T cells retrovirally transduced to express an A2-RMF low affinity Clone 45 
Human T cells transduced to express low affinity clone 45 was unable to bind A2-RMF 
Tetramer. Flow cytometry analysis was performed to evaluate the binding of HLA A0201 
RMF tetramer in GFP+ sorted population. 
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Figure 2.   
A2-RMF low affinity CAR T cells exhibit low cytotoxic activity against WT1 
expressing A0201+ tumor cells 
(A) The level of WT1 expression in different tumor cell line was confirmed by western 
blot analysis using anti WT-1 antibody. (B) Specific cytotoxicity of Clone 45-CAR T cells 
against the tumor cell lines by chromium release assay after sorted for GFP+ T cells. 
Samples were prepared in triplicate and values are shown as mean ± SE. Experiment 
was repeated twice with similar results. 
 
  
 
 
 
 
  
144
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	 	
anti-WT1 
			1								2								3									4								5									6								7								8							9				
‐5
0
5
10
15
20
25
30
35
40
25:1 10:1
Pe
rc
en
t Ly
sis
E:T Ratio
OVCAR3/pp65
HTB37/pp65
SKOV3
(A) 
(B) 
145
  
 
 
 
 
 
Figure 3. 
  Phenotypic and functional characterization of high affinity clone Q2L 
(A) K562 cells retrovirally transduced to express a high affinity clone Q2L. Flow 
cytometry analysis was performed to evaluate the binding of HLA A0201 RMF tetramer 
in GFP+ population. K562 non-transduced cells served as a control. (B) Human T cells 
transduced to express high affinity clone Q2L was able to bind A2-RMF Tetramer 
correlated with GFP+ transduced population. (C) Specific cytotoxicity of Q2L-CAR T 
cells against the tumor cell lines by chromium release assay. Samples were prepared in 
triplicate and values are shown as mean ± SE. Experiment was repeated twice with 
similar results. 
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Figure	3	(Continued)	
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Figure	3	(Continued)	
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THESIS DISCUSSION  
The efficacy of adoptive T-cell therapy, using naturally occurring antigen-specific 
T cells to treat patients with virus infections or cancers, is often limited by the 
failure of the T-cells to expand and persist in the patient for periods sufficient to 
induce eradication or control of the diseased cells and organs. Increasing 
evidence indicates that several attributes of the T-cells and the environment of 
the host contribute to or limit the functional	 longevity of the adoptively transferred 
T-cells. Among these are: the antigen	 specificity and avidity of the T-cells 
transferred, the stage of differentiation of the T-cells, their potential for sustained 
growth and their susceptibility to apoptosis or growth inhibition by regulatory T-
cells or myeloid suppressor cells. The persistence of allogenic T-cells is also 
determined by the potential of the host environment to provide cytokines and 
costimulating signals to sustain T-cell growth or, conversely, to generate 
alloreactive T-cells or antibodies to eliminate the T-cells or to generate inhibiting 
cells such as myeloid suppressor cells or regulatory T-cells. To develop an 
approach for enhancing persistence and overall efficacy of adoptive 
immunotherapy, this thesis has focused on comparatively evaluating the origins, 
phenotype and functional attributes of different memory T-cell subsets in 
humans, their proliferation and survival, as well as their in vivo homing and 
persistence. 
Memory T cells can be phenotypically sub classified based on distinct expression 
patterns of the lymph node–homing molecules CD62L and CCR7, into central 
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memory T cells (TCM) and effector memory T cells (TEM). The expression of CD95 
in naïve phenotype T cells further distinguishes a less differentiated memory T 
cell subset, termed stem cell memory T cells (TSCM) from the naïve T-cell 
population.  In this thesis, we performed a comparative analysis of different 
memory T-cell subsets in an antigen-specific T cell population, as well as their 
antigen non-responsive counterparts. We characterized HLA A0201 restricted TN, 
TSCM, TCM and TEM specific for the immunodominant NLV peptide of CMVpp65. 
Following in vitro sensitization the NLV specific Tet+ TN and TSCM derived cells 
expressed higher levels of CD27 and lower levels of CD57 than TCM or TEM, and 
expressed similar levels of KLRG-1 and PD-1, which were significantly higher 
than their Tet- counterparts (figure). At a functional level, antigen-specific TN, 
TSCM, TCM and TEM derived cells all contained cells capable of secreting TNF-α 
and IFN-γ, and expressed high levels of CD107a. Antigen-specific TSCM were 
distinguished from TN, TCM and TEM by a significantly greater level of proliferation 
and, from TN, by their rapid and selective expansion of antigen specific T-cells 
bearing TCR CDR3 sequences identical in sequence to those expressed by 
dominant, oligoclonal TEM and TCM in the blood. Taken together, our data suggest 
that antigen-specific TSCM are the principal reservoir for rapid repopulation of 
immunodominant T-cells in the circulation.  
In order for an immune response by cytotoxic T cells against a tumor to be 
effective, not only must antigen-specific T cells be generated to recognize the 
tumor, but these T cells must also be able to accumulate at tumor sites, and 
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thereafter physically contact and kill or otherwise suppress antigen-expressing 
cancer cell targets. The T-cells must also persist at tumor sites for periods 
sufficient to induce tumor eradication. A unique finding in our study is the 
disparity between the transient accumulations of the CMVpp65-specific TCM and 
TEM in the Cocapp65 tumor in the mice co-treated with IL-15/IL-15R and their 
persistence in the marrow of the same mice for more than 40 days after 
accumulation of T-cells in the tumors had decreased to levels no longer 
detectable by bioluminescence or by immunohistology. It is unclear why the 
CMV-specific T cells were able to persist in the marrow of the xenografted mice 
but failed to sustain the initial accumulation of the T-cells in the tumor 
environment to eradicate tumor.  
In our study, both TCM and TEM derived CMVpp65 specific T-cells differentially 
persisted in the bone marrow of NSG mice that received injections of the 
irradiated BAF-3 cells secreting high levels of IL-15 and IL-15/IL-15Rα complex. 
Similar to the findings of Wang el al. (21) in mice that did not receive IL-15 
secreting cell supplementation, neither TCM derived nor TEM derived T-cells were 
detected in the marrow of mice treated with IL-2. Unlike the findings of Wang et 
al. (21) in mice treated with NSO cells secreting low levels of IL-15 alone, the 
levels of TCM and TEM derived T-cells that persisted in the marrow of our mice 
were not significantly different. However, in agreement with their findings, we 
found that the T-cells in the marrow consisted exclusively of TEM and TE T-cells. 
We did not detect any T-cells exhibiting a CD45RO+CD62L+CCR7+ TCM 
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phenotype as has been described in primates infused with autologous CMV-
specific TEM and TE cells generated from TCM precursors in the blood. We did, 
however, observe that the TCM -derived TE cells persisting in the marrow differed 
from TEM -derived TE cells in that a proportion of these TE cells expressed IL-
15Rα, a finding also reported by Berger et al. (13) for TCM derived T-cells that 
persist long-term in non-human primates. The TCM-derived TE cells in the marrow 
were also able to proliferate and to generate IFN-γ in response to CMVpp65 
peptide indicating their functional competence. 
Since antigen-specific memory CD8+ T-cells have been shown to receive 
proliferative signals from IL-15 secreting cells in the marrow (33), and in human 
bone marrow, cells expressing IL-15R can trans-present IL-15 on their surface 
(32), it could explain why the bone marrow is the site where significant 
populations of CMVpp65-specific TEM derived T-cells are detected longterm.   
The possible reasons why both TCM and TEM derived CMVpp65 specific T-cells 
persisted in the marrow rather than the Coca pp65 tumor site might also be 
because of inhibitory signals from the tumor microenvironment and/or the lack of 
sustaining stimuli required by T cells. The inhibitory signals include PD1/PDL1, 
MDSCs or regulatory T cells. The high level of Fas (CD95) and PD1 expression 
that we detected on the CMVpp15-specific T cells might render the T cells in the 
tumor environment particularly susceptible to inhibition by PD-L1+ tumor cells, 
Fas ligand produced by myelomonocytic suppressor cells or other apoptosis-
promoting signals such as TNF-related apoptosis inducing ligand (TRAIL). The 
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inhibitory signal through PD1/PDL1 signaling is being examined by evaluating the 
level of PD-L1 expression on Coca pp65 tumor cells at different durations of 
growth in vivo. However, data from separate experiments in our lab have also 
shown that administration of anti-PD1 to mice treated with CMV-specific T cells 
enhanced antigen-specific tumor eradication compared to mice without anti-PD1 
treatment.  
In our NSG mouse model, it is hard to rule out the effect of MDSCs since the 
mouse myloid cells would cross-react with human CD8 T cells. However, there 
are no CD4+ Treg cells in our xenograft mouse model since we only transferred 
human CD8 T cells into the mice.  
A deficiency of essential stimuli required for the growth of antigen-specific T cells 
in the tumor could also explain our findings. For example, the CoCa pp65 tumor 
cells could downregulate HLA-A2 or critical costimulatory molecules. The T-cells 
could also lack cytokine support. In our Coca pp65 tumor model, we have 
evaluated the expression level of HLA-A2, B7.1, LFA-3 and ICAM-1 on our Coca 
pp65 tumor cell line. Of the costimulatory molecules, the level of B7.1 expression 
is relatively low (1% positive) compared to BLCLs (92% positive). Therefore, it is 
possible that the lack of sufficient co-stimulatory signaling through B7.1 could 
limit the persistence of T cells in the tumor. Down regulation of HLA-A2 in the 
tumor environment might also occur post transfer in NSG mice. Further 
experiments are needed to ascertain the level of HLA-A2 and costimulatory 
molecules in the tumor xenografts over time post transfer. In addition, since we 
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only transfer CD8 T cells into NSG mice, the lack of CD4 T cells in our model 
might also result in a lack of essential cytokine support in the tumor environment. 
T cells must also locally replicate to further increase their frequency, avoid being 
killed themselves by hostile elements of tumor microenvironment, and overcome 
barriers that restrict access to cancer cell targets. In this regard, findings in 
preclinical models and in patients with melanoma and other malignancies 
suggest that the tumor microenvironment may be the major site of clonal 
expansion of cancer-specific T-cells. Furthermore, the CD8+ T cell replicative 
response at this site is governed by  CD103+, Baft3-dependent dendritic cells, 
which can efficiently cross-present cancer cell antigens (82, 83). However, DC 
function may be adversely affected by hypoxic conditions characteristic of the 
tumor microenvironments that induce PD-L1 expression on DCs (84). These cells 
in the tumor microenvironment may also directly impair intratumoral T cell 
proliferation. Indole 2,3-dioxygenase (IDO) which can be expressed by DC, as 
well as myeloid derived suppressor cells and cancer cells, catabolizes tryptophan 
and generates hynurenine. Both the deprivation of tryptophan and the generation 
of its metabolic product inhibit clonal expansion (85, 86). Furthermore, both IDO 
and PD-L1 may not only may impair the intratumoral proliferation of effector T 
cells but may also induce apoptosis. 
Accumulating evidence also implicates other cell elements in the tumor 
microenvironment, particularly myelomonocytic cells, including several subsets of 
cells within the general designation of myeloid-derived suppressor cells (MDSCs) 
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and tumor associated macrophages (TAMs), as cells capable of restricting the 
sustained accumulation and effector function of T cells at sites of cancer cell 
growth (87-89). In addition, cancer-associated fibroblasts can regulate the spatial 
distribution of T cells within tumors, and can thus restrict direct contact of T-cells 
to tumor cell targets by providing a physical exclusion mediated by the 
extracellular matrix that they produce. Live cell imaging of lung tumor tissue 
slices from patients has revealed active T cell motility in regions of loose 
fibronectin and collagen, whereas T cells migrated poorly in dense matrix areas 
surrounding tumor nests (90). The tumor vasculature can also play an active role 
in restricting T cell entry. For example, the apoptosis inducer Fas ligand (FasL) is 
expressed in the tumor vasculature of multiple tumor types (91). In tumors with 
high levels of endothelial FasL, antigen-specific CD8 T cells might also be lost 
due to FasL-mediated killing through Fas (CD95) expressing T cells. Cells in the 
tumor microenvironment can also release chemokines that preferentially recruit 
certain immune cell types over others. In addition, posttranslational alterations in 
chemokines, such as chemokine nitration may prevent T-cell infiltration of the 
tumors (92).   
In summary, our studies of the CMVpp65-specific memory T-cell compartments 
suggest that TCM may accumulate to a greater degree in the antigen-bearing 
tumor xenografts but that neither TCM nor TEM persist long term in these sites. Our 
studies also clearly show that co-administration of IL-15/IL-15Rα prolongs the 
accumulation of T-cells in the CMVpp65+ tumor xenografts significantly beyond 
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that achieved with IL-2, and further, that IL-15/IL-15Rα supplementation fosters 
the long term persistence of functional CMVpp65-specific T-cells in the marrow. 
However, a major question that now needs to be addressed is: whether and to 
what degree the CMVpp65-specific T-cells detected in the marrow long term are 
capable of migrating to and inhibiting the growth of CMVpp65+ tumor xenografts 
after transfer into a secondary host. Simply put, are the CMVpp65-specific T-cells 
that persist in the marrow immune and able to provide meaningful resistance on 
secondary transfer or tolerized in the course of their contact with tumor and its 
environment. Alternatively, are these T-cells intrinsically different in their capacity 
to migrate to the CMVpp65+ tumor xenografts, (i.e. do they ever migrate to the 
tumor) or do they just migrate to the tumor and exert effector function, but then 
move to the marrow where their growth is better supported by the morrow 
environment. Experiments to address these issues are now being planned. 
In this thesis, I also examined whether increasing the TCR affinity of the 
endogenous TCRs for tumor antigen specific T-cells could enhance the activity of 
adoptively transferred T-cells directed against cancer antigens. The vast majority 
of tumor-associated peptide antigens recognized by CD8+ T cells originate from 
autologous proteins and, as such, remain protected by immune tolerance 
mechanisms configured to prevent autoimmunity (93). Indeed, as a consequence 
of thymic selection, cognate T cell receptor (TCR) binding to these self-derived 
epitopes occurs at substantially lower affinities compared to pathogen-specific 
TCRs (94). This distinction probably explains why naturally generated T cell 
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responses against cancer are largely non-protective (95). Moreover, the lack of 
high-affinity tumour-specific TCRs in the periphery may place intrinsic constraints 
on the efficacy of cancer vaccines designed to elicit T cell immunity. 
Antigen-specific TCR gene transfer into T cells is an attractive approach to 
cancer therapy, with the potential to break self-tolerance. Recent studies have 
suggested that the use of engineered, affinity-enhanced TCRs may circumvent 
immune apathy towards tumor-derived antigens. Approximating affinity to mimic 
optimal pathogen-specific TCRs (KD = 0.1–10 μM) also makes sense from the 
biological perspective (96, 97). Indeed, kinetic models of T cell activation propose 
that the potency of a T-cell specific for a peptide–major histocompatibility 
complex (pMHC) ligand is determined primarily by the duration of the TCR–
pMHC interaction (98). Potent T-cells generally bind with the highest affinities 
and longest half-lives, although many other parameters also affect T cell 
activation, antigen sensitivity and the response to TCR triggering (99, 100). 
Previous reports have described affinity threshold phenomena in other systems. 
In one study, a single cancer-specific TCR was used with mimotopes to generate 
a range of affinities up to 4-fold higher than the wild-type interaction (101). 
Although the highest-affinity mimotopes elicited the most vigorous responses in 
vitro, optimal anti-tumour activity in vivo was observed after vaccination with the 
intermediate affinity mimotopes. Two studies in the NY-ESO-1 system, spanning 
a range of TCR affinities up to 1430-fold greater than wild-type, reached similar 
conclusions (102, 103). In particular, target cell lysis was found to increase as a 
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function of affinity up to a threshold of ∼7 μM, beyond which further increments 
diminished killing activity. These findings were confirmed using a series of seven 
gp100-specific TCRs (104). Excessive affinity enhancement has also been 
shown to impair T cell function in the 2C system (105, 106). In addition, a recent 
study using APL vaccination in a diabetes/ovalbumin (OVA) mouse model 
showed that TCR affinity dictates not only the magnitude of T cell activation and 
target cell conjugation, but also the differentiation status of responding T cells 
(107). Similar observations have been reported for pathogen-specific TCRs 
(108). Thus, each system is constrained by an affinity ceiling, the parameters for 
which can be highly variable (109). 
In our study, we demonstrated that the affinity matured Q2L-CAR modified T 
cells recognized tumor cells in an HLA restricted WT1-specific fashion. In 
contrast, minimal target cell lysis was observed using T-cells expressing the low 
affinity parental Clone 45. Here we show that the affinity matured Q2L CAR can 
retain both target specificity and viability despite having high affinity (3nM KD for 
the scFv). Overall, both our own and other studies demonstrate higher cytolytic 
activity with increasing TCR /CAR binding affinity. T cell activation, signaling and 
subsequent function are limited to a given TCR-pMHC affinity window. As a 
result, optimal system-defined affinity windows above the range established for 
TCR/CAR avidity for specific antigens may allow the enhancement of T cell 
effector function without off-target effects. 
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Figure 
The role of antigen-experienced memory CD8 T cells 
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